Document:

EX-10.2

 EXHIBIT 10.2 

EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the
“Agreement”) is made and entered into effective as of June 9, 2015 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with
offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876, U.S.A. (“Intrexon”), Intrexon Actobiotics NV, a naamloze vennootschap under Belgian law with registered offices at Technologiepark 4, 9052 Zwijnaarde (CBE no.
0882.251.820 (Ghent), Belgium (“Actobiotics”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A.
(“Oragenics”). Intrexon and Actobiotics together on the one hand and Oragenics on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 

WHEREAS, Intrexon has expertise in and owns or controls proprietary technology relating to the
identification, design and production of genetically modified cells, DNA vectors and in vivo control of expression; 

WHEREAS, Actobiotics (formerly known as ActoGeniX NV and now legally operating under the name
above), a wholly-owned subsidiary of Intrexon, Controls proprietary technology known as AG013 and a related L. lactis expression platform; and 

WHEREAS, Oragenics now desires to become Intrexon’s exclusive channel collaborator with respect to
such technology for the purpose of developing the Program (as defined herein), and Intrexon is willing to appoint Oragenics as a channel collaborator in such field under the terms and conditions of this Agreement. 

NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained
herein, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 

As used in this Agreement, the following capitalized terms shall have the following meanings: 

1.1    “Actobiotics IP” means all Information, Patents, and proprietary biological materials that
(a) are Controlled by Actobiotics as of the Effective Date or during the Term and (b) are reasonably required or useful for Oragenics to conduct the Program. For the avoidance of doubt, the Actobiotics IP shall include the AG013 Regulatory
Rights, and any Information, Patents, and proprietary biological materials relating to AG013 and to other L. lactis strains under development that express human Trefoil Factor. 

1.2    “Affiliate” means, with respect to a particular Party, any other person or entity that
directly or indirectly controls, is controlled by, or is in common control with such Party. As 

 
used in this Section 1.2, the term “controls” (with correlative meanings for the terms “controlled by” and “under common control with”) means the ownership,
directly or indirectly, fifty percent (50%) or more of the voting securities or other ownership interest of an entity, or the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the
ownership of voting securities, by contract, or otherwise. Notwithstanding the foregoing, Third Security shall be deemed not to be an Affiliate of Intrexon or Oragenics, and neither Party shall be deemed to be an Affiliate of the other Party. In
addition, any other person, corporation, partnership, or other entity that would be an Affiliate of a Intrexon or Oragenics solely because it and Intrexon are under common control by Randal J. Kirk or by investment funds managed by Third Security or
an affiliate of Third Security shall also be deemed not to be an Affiliate of Intrexon or Oragenics. Further notwithstanding the foregoing, none of the KFLP Group shall be deemed to be an Affiliate of Oragenics, and any person, corporation,
partnership, or other entity that would otherwise be an Affiliate of Oragenics solely because it and Oragenics are under common control by a member of the KFLP Group shall not be deemed to be an Affiliate of Oragenics. 

1.3    “AG013” shall mean the existing drug product candidate as described in Investigational New
Drug application number 13995 filed with the FDA and under clinical development as of the Effective Date comprising genetically modified L. lactis that expresses a human Trefoil Factor and that is indicated for the treatment of oral
mucositis, which regulatory application, corresponding drug product candidate and intellectual property rights are owned by Actobiotics and licensed to Oragenics in accord with the terms and conditions of this Agreement. 

1.4    “AG013 Regulatory Rights” means all Information Controlled by Actobiotics (or otherwise by
Intrexon) and existing as of the Effective Date relating to the regulatory approval of AG013, including regulatory filings, data, clinical trial reports, and rights thereunder. 

1.5    “Applicable Laws” has the meaning set forth in Section 8.2(d)(xii). 

1.6    “Approval Milestone Event” means the first to occur for a particular Oragenics Product of
(i) the First Commercial Sale of such Oragenics Product anywhere in the Territory, or (ii) the ninetieth (90th) day after the approval of an FDA New Product Application for such
Oragenics Product by the FDA or equivalent regulatory action in a foreign jurisdiction. 

1.7    “Authorizations” has the meaning set forth in Section 8.2(d)(xii). 

1.8    “CC” has the meaning set forth in Section 2.2(b). 

1.9    “Channel-Related Program IP” has the meaning set forth in Section 6.1(c). 

1.10    “Claims” has the meaning set forth in Section 9.1. 

1.11    “CMCC” has the meaning set forth in Section 2.2(b). 

1.12    “Committees” has the meaning set forth in Section 2.2(a). 

  
 2 

 1.13    “Commercialize” or
“Commercialization” means any activities directed to marketing, promoting, distributing, importing for sale, offering to sell and/or selling Oragenics Products. 

1.14    “Commercialization Milestone Event” means any one of the Phase II Milestone Event, the
Phase IIb/III Milestone Event, the Regulatory Approval Application Milestone Event, the Approval Milestone Event, the New Indication Milestone Event, and the New Product Milestone Event. 

1.15    “Commercial Sale” means for a given product and country the sale for value of that product
by a Party (or, as the case may be, by an Affiliate or permitted sublicensee of a Party), to a Third Party after regulatory approval (if necessary) has been obtained for such product in such country. 

1.16    “Company Sale” means the sale of Oragenics, whether in a single transaction or in a series
of related transactions that are consummated contemporaneously (or consummated pursuant to contemporaneous agreements), to one or more Third Parties on an arm’s length basis, pursuant to which such Third Party or Third Parties acquires (i)
(whether by merger, consolidation, sale or transfer of capital stock, recapitalization, or otherwise) more than fifty percent (50%) of Oragenics’ common stock other than a Reverse Merger, or (ii) all or substantially all of the assets of
Oragenics determined on a consolidated basis. 
 1.17    “Complementary In-Licensed Third Party IP” has the meaning set forth in Section 3.8(a). 

1.18    “Confidential Information” means each Party’s confidential Information, inventions, non-public know-how or non-public data disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties
and shall include, without limitation, manufacturing, technical, marketing, financial, personnel and other business information and plans, whether in oral, written, graphic or electronic form. 

1.19    “Control” means, with respect to Information, a Patent or other intellectual property
right, that a Party owns or has a license from a Third Party to such right and has the ability to grant a license or sublicense as provided for in this Agreement under such right without violating the terms of any agreement or other arrangement with
any Third Party. 
 1.20    “CRC” has the meaning set forth in Section 2.2(b). 

1.21    “Diligent Efforts” means, with respect to a Party’s obligation under this Agreement,
the level of efforts and resources reasonably required to diligently develop, manufacture, and/or Commercialize (as applicable) each Oragenics Product in a sustained manner, consistent with the efforts and resources a similarly situated company
working in the Field would typically devote to a product of similar market potential, profit potential, strategic value and/or proprietary protection, based on market conditions then prevailing. With respect to a particular task or obligation,
Diligent Efforts requires that the applicable Party promptly assign responsibility for such task and consistently make and implement decisions and allocate resources designed to advance progress with respect to such task or obligation. 

  
 3 

 1.22    “Equity Agreement” has the meaning set
forth in Section 5.1. 
 1.23    “Excess Product Liability Costs” has the meaning set forth
in Section 9.3. 
 1.24    “Executive Officer” means : (i) the Chief Executive Officer of
the applicable Party, or (2) another senior executive officer of such Party who has been duly appointed by the Chief Executive Officer to act as the representative of the Party to resolve, as the case may be, (a) a Committee dispute,
provided that such appointed officer is not a member of the applicable Committee and occupies a position senior to the positions occupied by the applicable Party’s members of the applicable Committee, or (b) a dispute described in
Section 11.1. 
 1.25    “FDA” has the meaning set forth in Section 8.2(d)(xiii). 

1.26    “FDA New Product Application” means a “New Drug Application” or a
“Biologics License Application” (as both of such are defined according to relevant FDA guidelines and regulations establishing the mechanisms for the submission of new drug products in the United States of America for regulatory approval
prior to commercial sale and marketing), but excluding any Supplemental FDA Applications. 

1.27    “Field” means, irrespective of whether such requires regulatory approval, (i) the
treatment of oral mucositis in humans, (ii) the administration to humans of a trefoil factor via genetically modified bacteria (including L. lactis) for the treatment of diseases and conditions of the oral cavity, throat, and esophagus,
or (iii) both of (i) and (ii). Notwithstanding the foregoing, the Field shall exclude (a) the delivery of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, and (b) the Prior Field. For the sake of
clarity, the Field does include the amelioration of symptoms or complications of cancer (as opposed to the treatment of the cancer itself), including those symptoms or complications that are side effects of other cancer treatments, such as, for
example, the delivery of AG013 to treat oral mucositis in cancer patients. 
 1.28    “Field
Infringement” has the meaning set forth in Section 6.3(b). 
 1.29    “First Commercial
Sale” means, with respect to an Oragenics Product and country, the first sale to a Third Party of such Oragenics Product in such country after any necessary regulatory approvals and any necessary pricing or reimbursement approvals have been
obtained in such country. 
 1.30    “Fully Loaded Cost” means the direct cost of the applicable
good, product or service plus indirect charges and overheads reasonably allocable to the provision of such good, product or service in accordance with US GAAP. Subject to the approval of a project and its associated budget by the JSC, Intrexon
and/or Actobiotics will bill for its respective internal direct costs incurred through the use of annualized standard full-time equivalents; such rate shall be based upon the actual fully loaded costs of those personnel of Intrexon and its
Affiliates (including Actobiotics) directly involved in the provision of such good, product or service. Intrexon may, from time to time, adjust such full-time equivalent rate based on changes to its actual fully loaded costs and will review the
accuracy of its full-time equivalent rate at least quarterly. Intrexon and Actobiotics shall provide Oragenics with reasonable documentation indicating the basis for any direct costs (including costs charged to Intrexon and/or Actobiotics by JSC-authorized Third Party providers), indirect charges, any allocable overhead, and any such adjustment in full-time equivalent rate. 

  
 4 

 1.31    “Initial Financing Period” has the
meaning set forth in Section 10.2(e). 
 1.32    “Initial Study” means a study to be
conducted under the Program to determine according to pre-set criteria the next steps with respect to the advancement of AG013 as a clinical candidate, which study, guidelines, and criteria are described in a
written plan exchanged between and approved by the Parties prior to the Effective Date. 
 1.33    “In-Licensed Program IP” has the meaning set forth in Section 3.8(a). 

1.34    “Information” means information, results and data of any type whatsoever, in any tangible
or intangible form whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data
including pharmacological, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal information or descriptions. 

1.35    “Infringement” has the meaning set forth in Section 6.3(a). 

1.36    “Intrexon Channel Technology” means Intrexon’s current and future technology directed
towards the design, identification, culturing, and/or production of genetically modified cells, including without limitation the technology embodied in the Intrexon Materials and the Intrexon IP, and specifically including without limitation the
following of Intrexon’s platform areas and capabilities: (1) UltraVector®, (2) DNA and RNA MOD engineering, (3) protein engineering, (4) transcription control chemistry,
(5) genome engineering, (6) cell system engineering, and (7) the Actobiotics IP. 

1.37    “Intrexon Indemnitees” has the meaning set forth in Section 9.2. 

1.38    “Intrexon IP” means the Intrexon Patents and Intrexon
Know-How. 
 1.39    “Intrexon
Know-How” means all Information (other than Intrexon Patents) that (a) is Controlled by Intrexon as of the Effective Date or during the Term and (b) is reasonably required or useful for
Oragenics to conduct the Program. For the avoidance of doubt, the Intrexon Know-How shall include any Information (other than Intrexon Patents) in the Channel-Related Program IP and the AG013 Regulatory
Rights. 
 1.40    “Intrexon Materials” means the genetic code and associated amino acids and
gene constructs, in each case that are Controlled by Intrexon, used alone or in combination and such other proprietary reagents and biological materials including but not limited to plasmid vectors, virus stocks, cells and cell lines, antibodies,
and ligand-related chemistry, in each case that are reasonably required or provided to Oragenics by or on behalf of Intrexon to conduct the Program. 

1.41    “Intrexon Patents” means all Patents that (a) are Controlled by Intrexon as of the
Effective Date or during the Term; and (b) are reasonably required or useful for Oragenics to conduct the Program. For the avoidance of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP. 

  
 5 

 1.42    “Intrexon Trademarks” means those
trademarks related to the Intrexon Channel Technology that are established from time to time by Intrexon for use across its channel partnerships or collaborations. 

1.43    “Inventions” has the meaning set forth in Section 6.1(b). 

1.44    “IPC” has the meaning set forth in Section 2.2(b). 

1.45    “JSC” has the meaning set forth in Section 2.2(b). 

1.46    “KFLP” means the Koski Family Limited Partnership. 

1.47    “KFLP Group” means KFLP, each of its general partners, and Beverly Koski (as sole owner of
Koski Management, Inc.). 
 1.48     “Losses” has the meaning set forth in Section 9.1.

 1.49    “Net Sales” means, with respect to any Oragenics Product, the net sales of such
Oragenics Product by Oragenics, any Affiliates of Oragenics (including without limitation net sales of Oragenics Product to a non-Affiliate sublicensee but not including net sales by such non-Affiliate sublicensee), and any Product Sublicensees as determined in accordance with US GAAP as the gross amount invoiced on account of sales of Oragenics Product less the usual and customary discounts as
determined in accordance with US GAAP. In the case of any sale for value, such as barter or counter-trade other than in an arm’s length transaction exclusively for cash, Net Sales shall be deemed to be the net sales at which substantially
similar quantities of the product are sold for cash in an arm’s length transaction in the relevant country. If Oragenics Product is sold to any Third Party together with other products or services, the price of such product, solely for purposes
of the calculation of Net Sales, shall be deemed to be no less than the price at which such product would be sold in a similar transaction to a third party not also purchasing the other products or services. 

1.50    “New Indication Milestone Event” means the filing by or on behalf of Oragenics, or an
Affiliate or permitted sublicensee of Oragenics, of a Supplemental FDA Application with the FDA (or an equivalent filing with another equivalent regulatory agency) which Supplemental FDA Application seeks approval of an indication for use of an
Oragenics Product for a use other than the current regulatory-approved indication for the respective Oragenics Product. Notwithstanding the foregoing and in order to incentivize Oragenics to pursue new indications for the product AG013 in parallel
with the existing indication (as such existing indication is described in Investigational Drug Application no. 13995) for product AG013, the New Indication Milestone Event will be deemed not to have occurred if the filed regulatory package
under the prior sentence relies upon one or more human clinical trials for the specific new indication, which clinical trial(s) were conducted simultaneously and in parallel with human clinical trials underpinning the first-approved indication for
AG013. For the avoidance of doubt and clarification purposes, any occurrence of the New Indication Milestone Event shall not also be deemed the occurrence of the New Product Milestone Event or vice versa. 

  
 6 

 1.51    “New Product Milestone Event” means the
filing by or on behalf of Oragenics, or an Affiliate or permitted sublicensee of Oragenics, of a regulatory package with the FDA or with another equivalent regulatory agency, which regulatory package seeks approval of, or seeks permission to begin
human trials in support of approval of, a subject Oragenics Product that is deemed (according to relevant FDA guidelines) to be a different drug product than the first Oragenics Product that was clinically pursued under the Program. For purposes of
the New Product Milestone Event, the subject Oragenics Product shall be deemed to be a “different” Oragenics Product from the first Oragenics Product (and thus constitute an occurrence of the New Product Milestone Event) if regulatory
approval of the subject Oragenics Product must be obtained from the FDA under a different FDA New Product Application than the first Oragenics Product. For the avoidance of doubt and clarification purposes, any occurrence of the New Product
Milestone Event shall not also be deemed the occurrence of the New Indication Milestone Event or vice versa. 

1.52    “Oragenics Indemnitees” has the meaning set forth in Section 9.1. 

1.53    “Oragenics Independent IP” has the meaning set forth in Section 6.1(f). 

1.54    “Oragenics Product” means any product in the Field that is created, produced, developed,
or identified in whole or in part, directly or indirectly, by or on behalf of Oragenics during the Term through use or practice of Intrexon Channel Technology, Intrexon IP, Actobiotics IP, or the Intrexon Materials. For clarity, the continued
development and Commercialization of AG013 shall be pursued under the Program as an Oragenics Product. 

1.55    “Oragenics Program Patent” has the meaning set forth in Section 6.2(b). 

1.56    “Oragenics Termination IP” means all Patents or other intellectual property that Oragenics
or any of its Affiliates Controls as of the Effective Date or during the Term that cover, or is otherwise necessary or useful for, the development, manufacture or Commercialization of a Reverted Product or necessary or useful for Intrexon to operate
in the Field. Notwithstanding the foregoing, Oragenics Termination IP shall not include Oragenics Independent IP. 

1.57    “Patents” means (a) all patents and patent applications (including provisional
applications), (b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, requests for continued examination,
confirmations, re-examinations, extensions, supplementary protection certificates and the like of the foregoing, and (c) any foreign or international equivalents of any of the foregoing. 

1.58    “Phase II Milestone Event” means the first dosing of a patient by or on behalf of
Oragenics, or an Affiliate or permitted sublicensee of Oragenics, in a phase II clinical trial (as such is defined by relevant FDA guidelines) for a given Oragenics Product, irrespective of whether such occurs in the United States of America under
the jurisdiction of the FDA or elsewhere under the jurisdiction of a foreign regulatory agency. 

  
 7 

 1.59    “Phase IIb/III Milestone
Event” means the first to occur for a particular Oragenics Product of (i) the meeting of the primary endpoint by or on behalf of Oragenics, or an Affiliate or permitted sublicensee of Oragenics, in a phase IIb clinical trial (as such
is defined by relevant FDA guidelines wherein the subject clinical trial endpoints are designed to be sufficient for regulatory approval of the clinical product without a subsequent clinical phase III trial) for a given Oragenics Product,
irrespective of whether such occurs in the United States of America under the jurisdiction of the FDA or elsewhere under the jurisdiction of a foreign regulatory agency, or (ii) the meeting of the primary endpoint by or on behalf of Oragenics,
or an Affiliate or permitted sublicensee of Oragenics, in a phase III clinical trial (as such is defined by relevant FDA guidelines) for a given Oragenics Product, irrespective of whether such occurs in the United States of America under the
jurisdiction of the FDA or elsewhere under the jurisdiction of a foreign regulatory agency. 

1.60    “Prior Field” means the “Field” as recited and defined in Section 1.24 of
the prior “Exclusive Channel Collaboration Agreement” dated September 30, 2013 and previously executed by and between Intrexon and Oragenics. For clarity, the use of “Field” in the prior sentence does not have the meaning
ascribed in Section 1.27 of this Agreement. 
 1.61    “Product-Specific Program Patent”
means any issued Intrexon Patent where all the claims are directed to Inventions that relate solely and specifically to Oragenics Products. In the event of a disagreement between the Parties as to whether a particular Intrexon Patent is or is not a
Product-Specific Program Patent, the Parties shall seek to resolve the issue through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted to arbitration pursuant to
Section 11.2. Any Intrexon Patent that is subject to such a dispute shall be deemed not to be a Product-Specific Program Patent unless and until (a) Intrexon agrees in writing that such Patent is a Product-Specific Program Patent or
(b) an arbitrator or arbitration panel determines, pursuant to Article 11, that such Intrexon Patent is a Product-Specific Program Patent. 

1.62    “Product Sublicense” has the meaning set forth in Section 3.2(c). 

1.63    “Product Sublicensee” has the meaning set forth in Section 3.2(c). 

1.64    “Program” has the meaning set forth in Section 2.1(a). 

1.65    “Proposed Terms” has the meaning set forth in Section 11.2. 

1.66    “Prosecuting Party” has the meaning set forth in Section 6.2(c). 

1.67    “Recovery” has the meaning set forth in Section 6.3(f). 

1.68    “Regulatory Approval Application Milestone Event” means for a given Oragenics Product, the
first to occur of (a) the filing by Oragenics, an Affiliate thereof, or a permitted sublicensee thereof, of an FDA New Product Application with the FDA seeking approval of such Oragenics Product, or (b) the filing of an equivalent approval
or marketing application for such Oragenics Product with an equivalent regulatory authority in a foreign jurisdiction. 

  
 8 

 1.69    “Retained Product” has the meaning set
forth in Section 10.4(a). 
 1.70    “Reverse Merger” means the sale of Oragenics, whether
in a single transaction or in a series of related transactions that are consummated contemporaneously (or consummated pursuant to contemporaneous agreements), to one or more Third Parties on an arm’s length basis, pursuant to which such Third
Party or Third Parties acquire(s) via merger more than fifty percent (50%) of Oragenics’ common stock in a form of transaction wherein Oragenics is the surviving entity. 

1.71    “Reverted Product” has the meaning set forth in Section 10.4(c). 

1.72    “SEC” means the United States Securities and Exchange Commission. 

1.73    “Sublicensing Revenue” means any cash consideration, or the cash equivalent value of non-cash consideration, regardless of whether in the form of upfront payments, milestones, or royalties, actually received by Oragenics or its Affiliate from a Third Party in consideration for a grant of a
sublicense under the Intrexon IP or any rights to develop or Commercialize Oragenics Products, but excluding: (a) any amounts paid as bona fide reimbursement for research and development costs to the extent incurred following such grant;
(b) bona fide loans or any payments in consideration for a grant of equity of Oragenics to the extent that such consideration is equal to or less than fair market value (i.e. any amounts in excess of fair market value shall be Sublicensing
Revenue); (c) any amounts paid by Oragenics to a Third Party for the right to operate under or utilize Third Party owned intellectual property that is used to make or use an Oragenics Product underlying the Sublicensing Revenue, (d) subject to
the waiver provisions of Section 5.2(c), any payments received by Oragenics from permitted sublicensees for the achievement of a Commercialization Milestone Event that is the same as (or substantially similar to) a Commercialization Milestone
Event for which Intrexon is entitled to receive an equity-based milestone payment under Section 5.2(a), and (e) amounts received from sublicensees in respect of any Oragenics Product sales that are included in Net Sales and for which
Intrexon receives revenue sharing payments under Section 5.4(a). For clarity, Sublicensing Revenue includes milestone payments for Oragenics Products received by Oragenics from a sublicensee of Oragenics (including a Product Sublicensee) for
(i) the achievement by the Oragenics sublicensee of any milestone event that is not the same as, or substantially similar to, a Commercialization Milestone Event, (ii) the achievement by the Oragenics sublicensee of the second or
subsequent occurrence of the same (or substantially similar) Commercialization Milestone Event, irrespective of whether the first occurrence of the Commercialization Milestone Event in question was achieved by Oragenics, or its Affiliate or a
sublicensee, and (iii) the achievement by a permitted sublicensee of Oragenics of the first occurrence of the same (or substantially similar) Commercialization Milestone Event where Intrexon elects to share such milestone payment as
Sublicensing Revenue in accord with Section 5.2(c). 
 1.74    “Sublicensing Revenue Rate”
means a percentage of Sublicensing Revenue applicable to a proposed sublicense by Oragenics as follows: (a) with respect to any sublicense of an AG013 Oragenics Product (including new indications thereof), any revenues Oragenics receives from a
Product Sublicensee under a Product Sublicense that are not a percentage of Product Sublicensee’s Net Sales of Oragenics Products, and any amounts recovered under Section 6.3(f), the Sublicensing Revenue Rate shall be fifty percent (50%);
and (b) with respect to any other sublicense, the Sublicensing Revenue Rate shall be determined in accordance with Section 3.2. 

  
 9 

 1.75     “Superior Therapy” means a therapy in
the Field that, based on the data then available, (a) demonstrably appears to offer either superior efficacy or safety or significantly lower cost of therapy, as compared with both (i) those therapies that are marketed (either by Oragenics
or others) at such time for the indication and (ii) those therapies that are being actively developed by Oragenics for such indication; (b) demonstrably appears to represent a substantial improvement over such existing therapies; and
(c) has intellectual property protection and a regulatory approval pathway that, in each case, would not present a significant barrier to commercial development. 

1.76    “Supplemental FDA Application” means a “Supplemental New Drug Application” or a
“Supplemental Biologics License Application” (as both of such are defined according to relevant FDA guidelines and regulations establishing the mechanisms for the submission of data in support of the FDA granting approval for new, amended,
and/or expanded label indications for a prior-approved drug product in the United States of America). 

1.77    “Supplemental In-Licensed Third Party IP” has the
meaning set forth in Section 3.8(a). 
 1.78    “Support Memorandum” has the meaning set
forth in Section 11.2. 
 1.79    “Technology Access Fee” has the meaning set forth in
Section 5.1. 
 1.80    “Term” has the meaning set forth in Section 10.1. 

1.81    “Territory” means the entire world. 

1.82    “Third Party” means any individual or entity other than the Parties or their respective
Affiliates. 
 1.83    “Third Security” means Third Security, LLC. 

1.84     “US GAAP” means generally accepted accounting principles in the United States. 

1.85    “Work Plan” has the meaning set forth in Section 2.1(c). 

ARTICLE 2 

SCOPE OF CHANNEL COLLABORATION; MANAGEMENT 

2.1    Direction of the Program. 

(a)    Generally. The general purpose of the channel collaboration described in this Agreement will be to use
the Intrexon Channel Technology to research, develop and 

  
 10 

 
Commercialize products for use in the Field, including the continued development and Commercialization of AG013 (collectively, the “Program”). As provided below, the JSC shall
establish, monitor, and govern projects for the Program. Either Party may propose other potential projects in the Field for review and consideration by the JSC. 

(b)    Advancement of AG013; the Initial Study. The Parties have concluded that the Program would benefit
from the Initial Study being conducted before further other clinical activity is pursued for AG013, and, as such, have agreed that the Initial Study shall be conducted by Intrexon and/or Actobiotics under Section 4.7 immediately following the
Effective Date. Exhibit A contains a general description of the Initial Study, and Intrexon shall supply to Oragenics a complete study plan, in agreement with the parameters (including timing, budget, data evaluation criteria, and resulting
implications with respect to subsequent AG013 clinical activity) set forth in Exhibit A, for the Initial Study prior to commencement of the study. Following the completion of the Initial Study, the JSC will promptly meet and review the data
produced under the Initial Study and apply the criteria set forth in Exhibit A, with the purpose of determining the immediate clinical path forward for AG013 under the Program. 

(c)    Management via Work Plan. The Parties shall mutually draft and finalize at the JSC, within thirty
(30) days following completion of the Initial Study an initial version of a Program-wide work plan describing the development of Oragenics Products, including advancement of AG013 as an Oragenics Product, in the Field (“Work
Plan”), which Work Plan shall be adopted by the JSC. The Work Plan shall serve as a basis for the operation of the Program on a going-forward basis, and may be modified by the JSC subject to the rest of this Article 2, including to
introduce parallel research projects for the collaborative pursuit of new indications for AG013 and/or of new Oragenics Products in the Field. Notwithstanding the foregoing, the Parties (i) agree to conduct the Initial Study under the Program
beginning immediately after the Effective Date, and (ii) commit to have the JSC meet regularly prior to the finalization of the Work Plan in order to conduct and monitor, and to review the results of, the Initial Study in accord with
Section 2.1(b) above and to discuss other issues of relevance to the Program. 
 2.2    Committees.

 (a)    Generally. The Parties desire to establish several committees (collectively,
“Committees”) to oversee the Program and to facilitate communications between the Parties with respect thereto. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the
Committees shall have the obligation to exercise its authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith. 

(b)    Formation and Purpose. Promptly following the Effective Date, the Parties shall confer and then
create the JSC and the IPC, and, optionally, create one or more of the other Committees listed in the chart below. Each Committee shall have the purpose indicated in the chart. To the extent that after conferring both Parties agree to not create a
Committee (other than the JSC and the IPC), the creation of such Committee shall be deferred until one Party informs the other Party of its then desire to create the so-deferred Committee, at which point the
Parties will thereafter promptly create the so-deferred Committee and promptly schedule a meeting of such Committee within a reasonable time. 

  
 11 

			
	 Committee
	  	 Purpose

	Joint Steering Committee (“JSC”)	  	Establish projects for the Program and establish the priorities, as well as approve budgets for such projects. Approve all subcommittee projects and plans.
		
	Chemistry, Manufacturing and Controls Committee (“CMCC”)	  	Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the Program.
		
	Clinical/Regulatory Committee (“CRC”)	  	Review and approve all research and development plans and projects, including clinical projects, associated with any necessary regulatory approvals, all associated publications, and all regulatory filings and correspondence relating
to gaining regulatory approval under the Program; and review and approve itemized budgets with respect to the foregoing.
		
	Commercialization Committee (“CC”)	  	Establish project plans and review and approve activities and budgets for Commercialization activities under the Program.
		
	Intellectual Property Committee (“IPC”)	  	Evaluate intellectual property issues in connection with the Program; review and approve itemized budgets with respect to the foregoing.

 2.3    General Committee Membership and Procedure. 

(a)    Membership. For each Committee, each Party shall designate an equal number of representatives (not to
exceed four (4) for each Party) with appropriate expertise to serve as members of such Committee. For the JSC the representatives must all be employees of such Party or an Affiliate of such Party, and for Committees other than the JSC the
representatives must all be employees of such Party or an Affiliate of such Party with the caveat that each Party may designate for each such other Committee up to one (1) representative who is not an employee if : (i) such non-employee representative agrees in writing to be bound to the terms of this Agreement for the treatment and ownership of Confidential Information and Inventions of the Parties, and (ii) the other Party
consents to the designation of such non-employee representative, which consent shall not be unreasonably withheld. Each representative 

  
 12 

 
as qualified above may serve on more than one (1) Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee representatives at any time upon
written notice to the other Party. Each Committee shall have a chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which representative to the Committee
will act as chairperson shall alternate between the Parties, with Oragenics selecting the chairperson first for the JSC, CRC and CC, and Intrexon selecting the chairperson first for the CMCC and IPC. The chairperson of each Committee shall be
responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within fifteen (15) days thereafter. 

(b)    Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in no event
shall such meetings be held less frequently than once every six (6) months, with the caveat that both Parties may agree to suspend activities of a given Committee other than the JSC until such time as one Party informs the other Party of its
then desire to reactivate the so-suspended Committee, at which point the Parties will thereafter schedule and hold the next meeting for the reactivated Committee within one (1) month. Meetings of any
Committee may be held in person or by means of telecommunication (telephone, video, or web conferences). To the extent that a Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with Oragenics selecting the first meeting location for each Committee. A reasonable number of additional representatives of a Party may attend meetings of a Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in any Committee excepting that an Intrexon employee or agent serving on a Committee shall not prevent Intrexon from
recouping the Fully Loaded Costs otherwise derived from the labor of that employee or agent in the course of providing manufacturing or support services as set forth in Sections 4.6 and 4.7 below. 

(c)    Meeting Agendas. Each Party will disclose to the other proposed agenda items along with appropriate
information at least three (3) business days in advance of each meeting of the applicable Committee; provided, that a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose
that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for such Committee meeting. 

(d)    Limitations of Committee Powers. Each Committee shall have only such powers as are specifically
delegated to it hereunder or from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no Committee shall have any
power to amend this Agreement. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 12.7 below. Additionally, no member of any Committee shall be able to vote in such Committee and thereby bind
its respective Party on any material matter except as otherwise properly authorized, approved, or delegated by such Party in accord with Section 2.5. 

2.4    Committee Decision-Making. If a Committee is unable to reach unanimous consent on a particular matter
within thirty (30) days of its initial consideration of such matter, then either Party may provide written notice of such dispute to the Executive Officer of the other 

  
 13 

 
Party. The Executive Officers of each of the Parties will meet at least once in person or by means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their
good faith efforts to resolve the dispute within thirty (30) days after submission of such dispute to the Executive Officers. If any such dispute is not resolved by the Executive Officers within thirty (30) days after submission of such
dispute to such officers, then the Executive Officer of the Party specified in the applicable subsection below shall have the authority to finally resolve such dispute acting in good faith. 

(a)    Casting Vote at JSC. If a dispute at the JSC is not resolved pursuant to Section 2.4 above, then
the Executive Officer of Oragenics shall have the authority to finally resolve such dispute. 
 (b)    Casting
Vote at CMCC. If a dispute at the CMCC is not resolved pursuant to Section 2.4 above, then (i) in the case of any disputes relating to the Intrexon Materials, the manufacture of an Oragenics Product active pharmaceutical ingredient, or
the manufacturing of other components of Oragenics Products contracted for or manufactured by Intrexon, the Executive Officer of Intrexon shall have the authority to finally resolve such dispute; and (ii) in the case of any other disputes, the
Executive Officer of Oragenics shall have the authority to finally resolve such dispute. 
 (c)    Casting
Vote at CRC. If a dispute at the CRC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Oragenics shall have the authority to finally resolve such dispute. 

(d)    Casting Vote at CC. If a dispute at the CC is not resolved pursuant to Section 2.4 above, then
the Executive Officer of Oragenics shall have the authority to finally resolve such dispute. 
 (e)    Casting
Vote at IPC. If a dispute at the IPC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Intrexon shall have the authority to finally resolve such dispute, provided that such authority shall be shared by the Parties
with respect to Product-Specific Program Patents (i.e., neither Party shall have the casting vote on such matters, and any such disputes shall be resolved pursuant to Article 11). 

(f)    Other Committees. If any additional Committee other than those set forth in Section 2.2(b) is
formed, then the Parties shall, at the time of such formation, agree on which Party shall have the authority to finally resolve a dispute that is not resolved pursuant to Section 2.4 above. 

(g)    Restrictions. Neither Party shall exercise its right to finally resolve a dispute at a Committee in
accordance with this Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this Agreement; (ii) expands the obligations of the other Party under this Agreement;
(iii) negates any consent rights or other rights specifically allocated to the other Party under this Agreement; (iv) purports to resolve any dispute involving the breach or alleged breach of this Agreement; (v) resolves a matter if
the provisions of this Agreement specify that mutual agreement is required for such matter; or (vi) would require the other Party to perform any act that is inconsistent with applicable law. 

  
 14 

 2.5    Authorization of Committee Representatives. Each
representative serving on a Committee shall be responsible for ensuring that he or she acts only as duly authorized by its respective Party and obtains any advance approvals, delegations, or other authorizations from his or her respective Party in
advance of making any Committee votes. Any Committee representative shall only be able to bind its respective appointing Party via any Committee vote or other material Committee activity to the extent such vote or other activity has been previously
approved by the Party, is within the authority duly delegated to the representative by the respective Party, or is otherwise authorized by its respective Party as may be required by that Party’s corporate charter or bylaws, or by its board of
directors. Any action or vote taken without valid authority shall be considered null and void and shall be without effect unless subsequently approved by a vote in accord with this Section 2.5. 

ARTICLE 3 

LICENSE GRANTS 

3.1    Licenses to Oragenics. 

(a)    Subject to the terms and conditions of this Agreement, Intrexon and Actobiotics hereby grant to Oragenics a
license under the Intrexon IP and the Actobiotics IP to research, develop, use, import, export, make, have made, sell, and offer for sale Oragenics Products in the Field in the Territory. Such license shall be exclusive (even as to Intrexon and
Actobiotics) with respect to any clinical development, selling, offering for sale or other Commercialization of Oragenics Products in the Field, and shall be otherwise non-exclusive. 

(b)    Subject to the terms and conditions of this Agreement, Intrexon and Actobiotics hereby grant to Oragenics a non-exclusive, royalty-free license to use and display the Intrexon Trademarks and Actobiotics trademarks, solely in connection with the Commercialization of Oragenics Products, in the promotional materials,
packaging, and labeling for Oragenics Products, as provided under and in accordance with Section 4.9. 

(c)    Subject to the terms and conditions of this Agreement, Intrexon and Actobiotics hereby grant to Oragenics an
exclusive license in the Field under the AG013 Regulatory Rights, including an exclusive right in the Field to make reference to for purposes of conducting clinical trials and obtaining regulatory approval for AG013 as an Oragenics Product. 

3.2    Sublicensing. Except as provided in this Section 3.2, Oragenics shall not sublicense the rights
granted under Section 3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to research, develop, use, or Commercialize Oragenics Products or use or display the Intrexon
Trademarks, in each case except with Intrexon’s written consent, which written consent may be withheld in Intrexon’s sole discretion. The parties shall agree, in connection with any such sublicense not covered under Sections 3.2(a) through
3.2(c) below, on the applicable Sublicensing Revenue Rate with respect to such sublicense. Notwithstanding the foregoing, Oragenics (and its Product Sublicensees only to the extent set forth in Section 3.2(a) below) shall have a limited right
to sublicense under the circumstances described in Sections 3.2(a) through 3.2(c) below. 

  
 15 

 (a)    Oragenics may transfer, to the extent reasonably necessary
and after providing Intrexon with reasonable advance notice thereof, Intrexon Materials that are or that produce Oragenics Products to a Third Party contractor performing contract manufacturing responsibilities for Oragenics Products, and may in
connection therewith grant limited sublicenses necessary to enable such Third Party to perform such activities. If Oragenics transfers any Intrexon Materials under this Section 3.2(a), Oragenics will remain obligated to ensure that the rights
of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated by any such Third Party contractor. A Product Sublicensee of Oragenics may transfer, to the extent
reasonably necessary and upon the consent of Intrexon, which consent shall not be unreasonably withheld, Intrexon Materials that are or that produce ingredients for the Oragenics Product sublicensed by the Product Sublicensee to a Third Party
contractor performing on behalf of that Product Sublicensee contract manufacturing responsibilities for Oragenics Products, and may in connection therewith grant limited sublicenses to the extent necessary to enable such Third Party to perform such
activities. Oragenics will require and ensure that if any Product Sublicensee transfers any Intrexon Materials under this Section 3.2(a), that such Product Sublicensee, after obtaining Intrexon’s consent, will take commercially reasonable
steps, including contractually obligating any such Third Party contractors, to ensure that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated by any
Third Party contractors of such Product Sublicensees. 
 (b)    Oragenics may, with Intrexon’s written
consent, which written consent shall not be unreasonably withheld, conditioned, or delayed, sublicense the rights granted under Section 3.1 to an Affiliate, or transfer the Intrexon Materials to an Affiliate, or grant an Affiliate the right to
use or display the Intrexon Trademarks. In the event that Intrexon consents to any such grant or transfer to an Affiliate, Oragenics shall remain responsible for, and be guarantor of, the performance by any such Affiliate and shall cause such
Affiliate to comply with the provisions of this Agreement in connection with such performance (as though such Affiliate were Oragenics), including any payment obligations owed to Intrexon hereunder. 

(c)    Oragenics may grant a sublicense of the rights granted under Section 3.1 (and not including a right to
sublicense under this Section 3.2(c)) to a Third Party licensee of any Oragenics Product that is the subject of an effective Investigational New Drug Application or equivalent application or investigational exemption with a foreign regulatory
body (a “Product Sublicensee”) to the extent necessary to permit such Third Party to research, develop, use, import, export, make, have made, sell, and offer for sale that Oragenics Product (a “Product Sublicense”),
provided, that (i) such Product Sublicense is expressly limited to the appropriate Oragenics Product, (ii) such Product Sublicensee does not grant the Product Sublicensee any rights to Intrexon IP other than that incorporated into the
Oragenics Product at the time of the Product Sublicense, (iii) does not purport to relieve Oragenics of any of its obligations under this Agreement, (iv) the Product Sublicensee agrees in writing, in a document in form reasonably
acceptable to Intrexon and to which Intrexon is an express third party beneficiary, to abide by the following provisions of this Agreement: Sections 3.1., 3.3-3.6, 3.8, 3.10, and 3.11 and Articles 6, 7, and
10, (v) the Product Sublicense is presented in full to the JSC by Oragenics before execution by Oragenics and the prospective Product Sublicensee and as soon as is reasonably practical for the purpose of allowing the JSC to review and comment upon
the terms and scope of the Product Sublicense agreement before execution, and (vi) the Product Sublicensee is not controlled by or otherwise affiliated with a member of the KFLP Group. 

  
 16 

 3.3    Limitation on Sublicensees. None of the enforcement
rights under the Intrexon Patents that are granted to Oragenics pursuant to Section 6.3 shall be transferred to, or exercised by, a sublicensee except with Intrexon’s prior written consent, which may be withheld in Intrexon’s sole
discretion. 
 3.4    No Non-Permitted Use. Oragenics hereby
covenants that it shall not, nor shall it permit any Affiliate or, if applicable, (sub)licensee, to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or Intrexon Materials for any purposes other than those
expressly permitted by this Agreement. 
 3.5    Exclusivity. Intrexon, Actobiotics and Oragenics mutually
agree that, under the channel collaboration established by this Agreement, it is intended that the Parties will be exclusive to each other in the Field. To this end, neither Intrexon, Actobiotics, nor its Affiliates shall make the Intrexon Channel
Technology, Intrexon Materials or Actobiotics IP available to any Third Party for the purpose of developing or Commercializing products in the Field, and neither Intrexon nor any Affiliate shall pursue (either by itself or with a Third Party or
Affiliate) the research, development or Commercialization of any product for purpose of sale in the Field, outside of the Program. Further, other than Oragenics’ activities within the Program, neither Oragenics nor its Affiliates shall pursue
(either by itself or with a Third Party or Affiliate) the research, development or Commercialization of any product that uses, incorporates, references in a related regulatory filing, or is produced from Intrexon Channel Technology, Intrexon
Materials, or Intrexon IP for purpose of sale in the Field. 
 3.6    Off Label Use. For purpose of
clarity, (a) following the First Commercial Sale of an Oragenics Product, the use by direct or indirect purchasers or other users of Oragenics Products outside the Field (i.e. “off label use”) shall not constitute a breach by
Oragenics of the terms of Section 3.4 or 3.5, provided that neither Oragenics nor its Affiliate (nor any Third Party under contract with either of them) marketed or promoted Oragenics Products for such
off-label use; and (b) following the First Commercial Sale of a product by Intrexon, an Intrexon Affiliate, or a Third Party sublicensee, collaborator, or partner of Intrexon, the use by direct or
indirect purchasers or other users of such products in the Field (i.e. “off label use”) shall not constitute a breach by Intrexon of the terms of Section 3.5, provided that neither Intrexon nor its Affiliate (nor any Third Party under
contract with either of them) marketed or promoted such products for such off-label use. 

3.7    No Prohibition on Intrexon. Except as explicitly set forth in Sections 3.1 and 3.5, nothing in this
Agreement shall prevent Intrexon from practicing or using the Intrexon Materials, Intrexon Channel Technology, and Intrexon IP for any purpose, and to grant to Third Parties the right to do the same. Without limiting the generality of the foregoing,
Oragenics acknowledges that Intrexon has all rights, in Intrexon’s sole discretion, to make the Intrexon Materials, Intrexon Channel Technology (including any biological materials used in an Oragenics Product), and Intrexon IP available to
Third Party channel partners or collaborators for use in fields outside the Field. 

  
 17 

 3.8    Rights to Clinical and Regulatory Data. With the
exception of the AG013 Regulatory Rights, Oragenics shall own and control all clinical data and regulatory filings relating to Commercialization of Oragenics Products (except to the extent such become Reverted Products). Oragenics shall provide (or
shall cause any applicable Product Sublicensee to provide) full copies of all clinical and non-clinical data and reports, regulatory filings, and communications from regulatory authorities that relate
specifically and solely to Oragenics Products. To the extent that there exist any clinical and non-clinical data and reports, regulatory filings, and communications from regulatory authorities owned by
Oragenics (or a Product Sublicensee) that relate both to Oragenics Products and other products produced by Oragenics (or a Product Sublicensee) outside the Field, Oragenics shall provide (or shall cause any applicable Product Sublicensee to provide)
to Intrexon upon Intrexon’s request copies of the portions of such data, reports, filings, and communications that relate to Oragenics Products. Subject to its ongoing obligations of exclusivity under Section 3.5, Intrexon shall be
permitted, directly or in conjunction with or through partners or other channel collaborators, to reference this data, reports, filings, and communications relating to Oragenics Products in regulatory filings made to obtain regulatory approval for
products indicated for use in fields outside the Field. Intrexon shall have the right to use any such information in developing and Commercializing products outside the Field and to license any Third Parties to do so. 

3.9    Third Party Licenses. 

(a)    Intrexon shall obtain, at its sole expense, any licenses from Third Parties that are required in order to
practice the Intrexon Channel Technology in the Field where the licensed intellectual property is reasonably necessary for Intrexon to conduct genetic and cell engineering and related analytic activities under JSC established plans for the Program
(but excluding intellectual property directed to any specific target genes, cells lines or genetic transformation methodologies) (“Supplemental In-Licensed Third Party IP”). Other than with
respect to Supplemental In-Licensed Third Party IP, Oragenics shall be solely responsible for obtaining, at its sole expense, any licenses from Third Parties that Oragenics determines, in its sole discretion,
are required in order to lawfully make, use, sell, offer for sale, or import Oragenics Products (“Complementary In-Licensed Third Party IP”). Supplemental
In-Licensed Third Party IP and Complementary In-Licensed Third Party IP are collectively referred to as “In-Licensed
Program IP”. 
 (b)    In the event that either Party desires to license from a Third Party any
Supplemental In-Licensed Third Party IP or Complementary In-Licensed Third Party IP, such Party shall so notify the other Party, and the IPC shall discuss such In-Licensed Program IP and its applicability to the Oragenics Products and to the Field. As provided above in Section 3.9(a), Intrexon shall have the sole right and responsibility to pursue a license under
Supplemental In-Licensed Third Party IP, and Oragenics hereby covenants that it shall not itself directly license such Supplemental In-Licensed Third Party IP at any
time, provided that Oragenics may (but shall not be obligated to) obtain such a license directly if the Third Party owner or licensee of such Supplemental In-Licensed Third Party IP brings an
infringement action against Oragenics or its Affiliates or threatens to bring such action (solely to the extent such threats would reasonably be considered to subject the Third Party owner or licensee to declaratory judgment action jurisdiction)
and, after written notice to Intrexon of such action, Intrexon fails to obtain a license to such Supplemental In-Licensed Third Party IP using Diligent Efforts within ninety

  
 18 

 
(90) days after such notice. Following the IPC’s discussion of any Complementary In-Licensed Third Party IP, subject to Section 3.9(c), Oragenics
shall have the right to pursue a license under Complementary In-Licensed Third Party IP, at Oragenics’ sole expense. For the avoidance of doubt, Intrexon may at any time obtain a license under
Complementary In-Licensed Third Party IP outside the Field, at Intrexon’s sole expense, provided that if Intrexon decides to seek to obtain such a license, it shall use reasonable efforts to
coordinate its licensing activities in this regard with Oragenics. 
 (c)    Oragenics shall provide the proposed
terms of any license under Complementary In-Licensed Third Party IP and the final version of the definitive license agreement for any Complementary In-Licensed Third
Party IP to the IPC for review and discussion prior to signing, and shall consider Intrexon’s comments thereto in good faith. To the extent that Oragenics obtains a license under Supplemental In-Licensed
Third Party IP, Oragenics shall provide the final version of the definitive license agreement for such Supplemental In-Licensed Third Party IP to the IPC. If Oragenics acquires rights under any In-Licensed Program IP outside the Field, it will do so on a non-exclusive basis unless it obtains the prior written consent of Intrexon for such license outside the Field to
be exclusive. Any Party that is pursuing a license to any In-Licensed Program IP with respect to the Field under this Section 3.9 shall keep the other Party reasonably informed of the status of any
negotiations relating thereto. For purposes of clarity, (i) any costs incurred by Intrexon in obtaining and maintaining licenses to Supplemental In-Licensed Third Party IP shall be borne solely by
Intrexon, and (ii) any costs incurred by Oragenics in obtaining and maintaining licenses to Complementary In-Licensed Third Party IP (and, to the limited extent provided in subsection (b), Supplemental In-Licensed Third Party IP) shall be borne solely by Oragenics. 
 (d)    For
any Third Party license under which Oragenics or its Affiliates obtain a license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture, and/or
Commercialization of Oragenics Products, Oragenics shall use commercially reasonable efforts to ensure that Oragenics will have the ability, pursuant to Section 10.4(h), to assign such agreement to Intrexon or grant a sublicense to Intrexon
thereunder (having the scope set forth in Section 10.4(h)). 
 (e)    The licenses granted to Oragenics
under Section 3.1 may include sublicenses under Intrexon IP that has been licensed to Intrexon by one or more Third Parties. Any such sublicenses are subject to the terms and conditions set forth in the applicable upstream license agreement,
subject to the cost allocation set forth in Section 3.9(c), provided that Intrexon shall either provide unredacted copies of such upstream license agreements to Oragenics or shall disclose in writing to Oragenics all of such terms
and conditions that are applicable to Oragenics. Oragenics shall not be responsible for complying with any provisions of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to Oragenics as provided in
the preceding sentence. 
 (f)    If either Party receives notice from a Third Party concerning activities of a
Party taken in conjunction with performance of obligations under this Agreement, which notice alleges infringement by a Party of, or offers license under, Patents or other intellectual property rights owned or controlled by that Third Party, the
receiving Party shall inform the other party thereof within five (5) business days. 

  
 19 

 3.10    Licenses to Intrexon. Subject to the terms and
conditions of this Agreement, Oragenics hereby grants to Intrexon a non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property Controlled by
Oragenics or its Affiliates, solely to the extent necessary for Intrexon to conduct those responsibilities assigned to it under this Agreement, which license shall be sublicensable solely to Intrexon’s Affiliates or to any Intrexon
subcontractors as permitted in accord with Section 4.6 or as otherwise permitted to be used by Intrexon in conjunction with support services under Section 4.7 (subject to JSC research plan approval) 

3.11    Restrictions Relating to Intrexon Materials. Oragenics and its permitted sublicensees shall use the
Intrexon Materials solely for purposes of the Program and not for any other purpose without the prior written consent of Intrexon. With respect to the Intrexon Materials comprising Intrexon’s vector assembly technology, Oragenics shall not, and
shall ensure that Oragenics personnel and permitted sublicensees do not, except as otherwise expressly permitted under this Agreement, (a) distribute, sell, lend or otherwise transfer such Intrexon Materials to any Third Party; (b) co-mingle such Intrexon Materials with any other proprietary biological or chemical materials without Intrexon’s written consent; or (c) analyze such Intrexon Materials or in any way attempt to
reverse engineer or sequence such Intrexon Materials. 
 ARTICLE 4 

OTHER RIGHTS AND OBLIGATIONS 

4.1    Development and Commercialization. Subject to Sections 4.6 and 4.7, Oragenics shall be solely
responsible for the development and Commercialization of Oragenics Products in the Field. Oragenics shall be responsible for all costs incurred in connection with the Program except that Intrexon shall be responsible for the following:
(a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through
depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing an Oragenics Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon
Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of an Oragenics Product (which research costs shall be reimbursed by Oragenics); (c)
payments under Section 3.9(c)(i) in respect of Supplemental In-Licensed Third Party IP; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within clause
(a) of the previous sentence shall include the scale-up of Intrexon Materials for generating data for regulatory approval submissions and Commercialization of Oragenics Products undertaken pursuant to
Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Oragenics (with Intrexon’s consent). 

4.2    Transfer of Technology and Information. The JSC shall develop a plan and protocol for each project
and timing for the transfer of relevant data and Intrexon Materials. 

  
 20 

 4.3    Information and Reporting. Oragenics will keep
Intrexon informed about Oragenics’ efforts to develop and Commercialize Oragenics Products, including reasonable and accurate summaries of Oragenics’ (and its Affiliates’ and, if applicable, (sub)licensees’) global development
plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments
in the development and/or Commercialization of the Oragenics Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or
international regulatory filing, clinical or product safety event, receipt of regulatory approval or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics shall also provide to Intrexon
copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics as soon as practical after they become available. Intrexon will keep Oragenics informed
about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and
(b) to undertake discovery-stage research for the Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by
Oragenics and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Oragenics Products are being developed or Commercialized anywhere in the world, and shall be reflected in
the minutes of such meetings. 
 4.4    Regulatory Matters. At all times after the Effective Date,
Oragenics shall own and maintain, at its own cost, all regulatory filings and regulatory approvals for Oragenics Products that Oragenics is developing or Commercializing pursuant to this Agreement. As such, Oragenics shall be responsible for
reporting all adverse events related to such Oragenics Products to the appropriate regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of such countries. To the extent that Intrexon will itself
develop, or in collaboration with other third parties develop, Intrexon Materials outside of the Field, Intrexon may request that Oragenics and Intrexon establish and execute a separate safety data exchange agreement, which agreement will address
and govern the timely exchange of safety information generated by Oragenics, Intrexon, and relevant third parties with respect to specific Intrexon Materials. The decision to list or not list Patents in any regulatory filing for an Oragenics Product
(for example, as required by 21 C.F.R. § 314.53(b)), add or delete a Patent from a regulatory filing, or to otherwise identify a Patent to a third party in compliance with laws or regulations relating to regulatory approvals (for example, in
compliance with 42 U.S.C. § 262(a)(1)(A)(k) et seq.) shall be determined by Intrexon, after consultation with Oragenics, except with respect to Product Specific Program Patents, which will be mutually determined by the Parties. 

4.5    Diligence. 

(a)    Oragenics shall use, and shall require its Product Sublicensees to use, Diligent Efforts to develop and
Commercialize Oragenics Products. 

  
 21 

 (b)    Without limiting the generality of the foregoing, Intrexon
may, from time to time, notify Oragenics that it believes it has identified a Superior Therapy, and in such case Intrexon shall provide to Oragenics its then-available information about such therapy and reasonable written support for its conclusion
that the therapy constitutes a Superior Therapy. Oragenics shall have the following obligations with respect to such proposed Superior Therapy: (i) within sixty (60) days after such notification, Oragenics shall prepare and deliver to the
JSC for review and approval a development plan detailing how Oragenics will pursue the Superior Therapy (including a proposed budget); (ii) Oragenics shall revise the development plan as directed by the JSC; and (iii) following approval of the
development plan by the JSC, Oragenics shall use Diligent Efforts to pursue the development of the Superior Therapy under the Program in accordance with such development plan. If Oragenics fails to comply with the foregoing obligations, or if
Oragenics unreasonably exercises its casting vote at the JSC to either (x) prevent the approval of a development plan for a Superior Therapy; (y) delay such approval more than sixty (60) days after delivery of the development plan to
the JSC; or (z) approve a development plan that is insufficient in view of the nature and magnitude of the opportunity presented by the Superior Therapy, then Intrexon shall have the termination right set forth in Section 10.2(c) (subject
to the limitation set forth therein). For clarity, any dispute arising under this 4.5, including any dispute as to whether a proposed project constitutes a Superior Therapy (as with any other dispute under this Agreement) shall be subject to dispute
resolution in accordance with Article 11. 
 (c)    The activities of Oragenics’ Affiliates and any
permitted sublicensees shall be attributed to Oragenics for the purposes of evaluating Oragenics’ fulfillment of the obligations set forth in this Section 4.5. 

4.6    Manufacturing. Intrexon shall have the option and, in the event it so elects, shall use Diligent
Efforts, to perform any manufacturing activities in connection with the Program that relate to the Intrexon Materials, including through the use of a suitable Third Party contract manufacturer. To the extent that Intrexon so elects, Intrexon may
request that Oragenics and Intrexon establish and execute a separate manufacturing and supply agreement, which agreement will establish and govern the production, quality assurance, and regulatory activities associated with manufacture of Intrexon
Materials. Except as provided in Section 4.1, any manufacturing undertaken by Intrexon pursuant to the preceding sentence shall be performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in connection with such
manufacturing, on terms to be negotiated by the Parties in good faith. In the event that Intrexon does not manufacture Intrexon Materials, bulk drug product or bulk quantities of other components of Oragenics Products, then Intrexon shall provide to
Oragenics or a contract manufacturer selected by Oragenics and approved by Intrexon all Information Controlled by Intrexon that is (a) related to the manufacturing of such Intrexon Materials, bulk drug product or bulk qualities of other
components of Oragenics Products, for use in the Field and (b) reasonably necessary to enable Oragenics or such contract manufacturer (as appropriate) for the sole purpose of manufacturing such Intrexon Materials, bulk drug product or bulk
quantities of other components of Oragenics Products. The costs and expenses incurred by Intrexon in carrying out such transfer shall be borne by Intrexon. Any manufacturing Information transferred hereunder to Oragenics or its contract manufacturer
shall not be further transferred to any Third Party, including any Product Sublicensee, or any Oragenics Affiliate without the prior written consent of Intrexon; provided, however, that Intrexon shall not unreasonably withhold such consent if
necessary to permit Oragenics to switch manufacturers. 

  
 22 

 4.7    Support Services. The study plan produced by
Intrexon under Section 1.2(b) and the Work Plan shall describe tasks by which Intrexon (by itself, through its Affiliates (including Actobiotics), or through designated Third Parties) will provide support services to Oragenics for the research
and development of Oragenics Products under the Program, which tasks may be updated or amended from time to time by the JSC. Oragenics will compensate Intrexon for such support services with cash payments equal to Intrexon’s Fully Loaded Cost
in connection with such services. Additionally, from time to time, on an ongoing basis, Oragenics shall request, or Intrexon may propose, that Intrexon (by itself, through its Affiliates (including Actobiotics), or through designated Third Parties)
perform certain additional support services with respect to the Program. To the extent that the Parties mutually agree that Intrexon (or its Affiliates (including Actobiotics) should perform such additional services, the Parties shall negotiate in
good faith the terms under which services would be performed, it being understood that Intrexon and/or Actobiotics (as appropriate) would be compensated for such services by cash payments equal to their Fully Loaded Cost in connection with such
services. 
 4.8    Compliance with Law. Each Party shall comply, and shall ensure that its Affiliates,
(sub)licensees and Third Party contractors comply, with all applicable laws, regulations, and guidelines applicable to the Program, including without limitation those relating to the transport, storage, and handling of Intrexon Materials and
Oragenics Products. 
 4.9    Trademarks and Patent Marking. To the extent permitted by applicable law and
regulations, Oragenics shall, and shall ensure that the packaging, promotional materials, and labeling for Oragenics Products, as appropriate, shall carry, in a conspicuous location, the applicable Intrexon Trademark(s), subject to Oragenics’
reasonable approval of the size, position, and location thereof. Consistent with the U.S. patent laws, Oragenics shall ensure that Oragenics Products, or their respective packaging or accompanying literature as appropriate, bear applicable and
appropriate patent markings for Intrexon Patent numbers. Oragenics shall provide Intrexon with copies of any materials containing the Intrexon Trademarks or patent markings prior to using or disseminating such materials, in order to obtain
Intrexon’s approval thereof. Oragenics’ use of the Intrexon Trademarks and patent markings shall be subject to prior review and approval of the IPC. Oragenics acknowledges Intrexon’s sole ownership of the Intrexon Trademarks and
agrees not to take any action inconsistent with such ownership. Oragenics covenants that it shall not use any trademark confusingly similar to any Intrexon Trademarks in connection with any products (including any Oragenics Product). From time to
time during the Term, Intrexon shall have the right to obtain from Oragenics samples of Oragenics Product sold by Oragenics or its Affiliates or sublicensees, or other items which reflect public uses of the Intrexon Trademarks or patent markings,
for the purpose of inspecting the quality of such Oragenics Products, the use of the Intrexon Trademarks, or the accuracy of the patent markings. In the event that Intrexon inspects under this Section 4.9, Intrexon shall notify the result of
such inspection to Oragenics in writing thereafter. Oragenics shall comply with reasonable policies provided by Intrexon from time-to-time to maintain the goodwill and
value of the Intrexon Trademarks. 
 4.10    Reporting Compliance. During the Term, in the event that
Intrexon notifies Oragenics that Intrexon has reasonably concluded, after consultation with its outside advisors, that Intrexon will be required to consolidate Oragenics’ financial statements with its own or otherwise incorporate summary
financial information of Oragenics in one of or more of Intrexon’s financial reports and filings as required by US GAAP or SEC requirements, Oragenics shall comply with the additional obligations set forth below in this Section 4.10.

  
 23 

 (a)    Oragenics shall keep its books and records consistent with
US GAAP. 
 (b)    Oragenics shall provide to Intrexon a complete set of draft basic financial statements
and a draft of Oragenics’ Form 10-Q within twenty-eight (28) days after the end of the calendar quarter. Such financial statements may be unaudited and should be prepared in accordance with SEC and
US GAAP requirements. Additionally, if not otherwise disclosed in any such draft Form 10-Q of Oragenics, Oragenics shall provide Intrexon with its anticipated cash dry date concurrent with providing the
draft Form 10-Q. 
 (c)    Oragenics shall provide to Intrexon a complete
set of draft audited financial statements, including accompanying footnotes, as of and for the end of each fiscal year and a draft of Oragenics’ Form 10-K within sixty (60) days after the end of such
fiscal year. Such financial statements must be prepared in accordance with SEC and US GAAP requirements. Additionally, if not otherwise disclosed in any such Form 10-K of Oragenics, Oragenics shall
provide Intrexon with its anticipated cash dry date concurrent with providing the draft Form 10-K. 

(d)    Oragenics shall communicate in writing as soon as practical to Intrexon any material weaknesses or
significant deficiencies in internal accounting controls as well as context regarding the cause and planned disposition of such material weakness or significant deficiencies. 

(e)    Oragenics shall communicate in writing as soon as practical to Intrexon any adverse event which may result
in a material adjustment to the carrying value of Intrexon’s holdings in Oragenics securities. 

(f)    Oragenics shall provide to Intrexon, within a reasonable time frame, any other items related to Oragenics
operations that may be reasonably requested by Intrexon to meet its compliance requirements under applicable laws and regulations, including filing requirements with the SEC and any other regulators. 

(g)    Oragenics shall work with its external auditors to cause any necessary auditor consents or other items
needed from such external auditors to be provided timely to Intrexon in order for Intrexon to meet any SEC filing requirements or other compliance requirements under applicable laws and regulations. 

4.11    Modification of Deadlines. The parties agree that the delivery deadlines in Section 4.10 will
be modified to the extent necessary to ensure that such deliverables are provided by Oragenics in a reasonable time frame prior to the date necessary for Intrexon to meet any disclosure obligation under rules or regulations to which Intrexon may be
or become subject from time to time. Intrexon will provide Oragenics with notice as promptly as practicable regarding any changes in Intrexon’s disclosure obligations that would require a change in delivery deadlines or cure periods per this
Section 4.11. 

  
 24 

 4.12    Transfer of Information. Promptly following the
Effective Date and in order to support timely adoption of the Work Plan by the JSC, Intrexon shall promptly provide to Oragenics copies of relevant data, regulatory approvals and regulatory filings that relate to the development and clinical testing
of AG013. Thereafter, as additional projects are included in the Program, the JSC shall develop a plan and protocol for each such project relating to the transfer of relevant data and Intrexon Materials. 

ARTICLE 5 

COMPENSATION 

5.1    Technology Access Fee. In partial consideration for Oragenics’ appointment as an exclusive
channel collaborator in the Field and the other rights granted to Oragenics hereunder, contemporaneously with the execution of this Agreement Oragenics shall deliver to Intrexon a note in the amount of five million United States dollars ($5,000,000)
(the “Technology Access Fee”) to Intrexon, all in accordance with the terms and conditions of that certain Stock Issuance Agreement of even date herewith (the “Equity Agreement”). Provided that all closing
conditions for the full payment of the fee under this Section 5.1 to Intrexon as set forth in the Equity Agreement that are within the reasonable control of Intrexon have been satisfied or waived, the full payment to Intrexon of the Technology
Access Fee (including the final issuance of any shares by Oragenics as payment therefor per the terms and conditions set forth in the Equity Agreement) is a condition subsequent to the effectiveness of this Agreement. 

5.2    Milestones. 

(a)    Oragenics Commercialization Milestones. Upon the attainment of certain Commercialization Milestone
Events by an Oragenics Product (whether such attainment is achieved by Oragenics or by a permitted sublicensee), Oragenics has agreed to pay Intrexon milestone payments as set forth in this Section 5.2. The milestone payments are each payable,
at Oragenics’ election but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’ common stock (using Fair Market Value, as defined in the Equity Agreement, to calculate the number of shares to be issued to
Intrexon in lieu of cash). The specific milestone payments due to Intrexon upon achievement of each of the Commercialization Milestone Events are set forth in Sections 5.2(a)(i) through 5.3(a)(vi) below. 

(i)    Oragenics shall pay Intrexon a milestone payment of two million United States dollars ($2,000,000) within thirty
(30) days of each achievement of the Phase II Milestone Event for each different Oragenics Product, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’
common stock. A second or a subsequent occurrence of the Phase II Milestone Event shall only give rise to an obligation upon Oragenics to make the payment to Intrexon under this Section 5.2(a)(i) if such respective second or subsequent
occurrence of the Phase II Milestone Event occurs after the FDA has granted an approval to an FDA New Product Application for at least one Oragenics Product under the Program. 

(ii)    Oragenics shall pay Intrexon a milestone payment of five million United States dollars ($5,000,000) within thirty
(30) days of each achievement of the Phase 

  
 25 

 
IIb/III Milestone Event for each different Oragenics Product, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of
Oragenics’ common stock. A second or a subsequent occurrence of the Phase IIb/III Milestone Event shall only give rise to an obligation upon Oragenics to make the payment to Intrexon under this Section 5.2(a)(ii) if such respective second
or subsequent occurrence of the Phase IIb/III Milestone Event occurs after the FDA has granted an approval to an FDA New Product Application for at least one Oragenics Product under the Program. 

(iii)    Oragenics shall pay Intrexon a milestone payment of five million United States dollars ($5,000,000) within
thirty (30) days of each achievement of the Regulatory Approval Application Milestone Event for each different Oragenics Product, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash
or in shares of Oragenics’ common stock. A second or a subsequent occurrence of the Regulatory Approval Application Milestone Event shall only give rise to an obligation upon Oragenics to make the payment to Intrexon under this
Section 5.2(a)(iii) if such respective second or subsequent occurrence of the Regulatory Approval Application Milestone Event occurs after the FDA has granted an approval to an FDA New Product Application for at least one Oragenics Product
under the Program. 
 (iv)    Oragenics shall pay Intrexon a milestone payment of ten million United States dollars
($10,000,000) within thirty (30) days of each achievement of the Approval Milestone Event for each different Oragenics Product, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or
in shares of Oragenics’ common stock. 
 (v)    Oragenics shall pay Intrexon a
one-time milestone payment of five million United States dollars ($5,000,000) within thirty (30) days of the first instance of the achievement of the New Indication Milestone Event, said payment being
made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’ common stock. 

(vi)    Oragenics shall pay Intrexon a one-time milestone payment of five million
United States dollars ($5,000,000) within thirty (30) days of the first instance of the achievement of the New Product Milestone Event, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in
cash or in shares of Oragenics’ common stock. 
 For purposes of subsections (i) through (iv) above in this Section 5.2(a), a later Oragenics
Product shall be deemed to be a “different” Oragenics Product from an earlier Oragenics Product (and thus trigger a subsequent occurrence of the respective milestone payment obligation under any one of subsections (i) through (iv)) if
regulatory approval of the later Oragenics Products must be obtained from the FDA under a different FDA New Product Application than the earlier Oragenics Product. Conversely and for clarity, a later Oragenics Product shall not be deemed
“different” from an earlier Oragenics Product for these milestones if the respective Commercialization Milestone Event occurs in support of a supplemental FDA New Drug Product Application that was being pursued to obtain labeling approval
for new, added, expanded, or amended indications for an earlier Oragenics Product that had already obtained 

  
 26 

 
FDA approval (i.e., the respective milestone shall not be triggered a second time in these instances of Oragenics pursuing new indications for pre-existing
and pre-approved Oragenics Products). Notwithstanding anything in this Agreement to the contrary, but subject to its obligation under Section 4.5(a), Oragenics shall have sole and exclusive control over
clinical trials (including patient dosing) and regulatory filings (including the jurisdictions in which such filings are made) for the purpose of the Commercialization Milestones in Section 5.2(a)(i)-(vi) as applicable. 

(b)    Milestones After Company Sale or After Reverse Merger. In the event that Oragenics consummates a
Company Sale prior to paying to Intrexon any one or more of the respective milestone payments set forth in Sections 5.2(a)(i) through 5.2(a)(vi) and this Agreement is transferred or assigned to the buyer in connection with such Company Sale, then
all subsequent payments for Commercialization Milestone Events shall thereafter each be payable only in cash to Intrexon. In the event that Oragenics consummates a Reverse Merger, subsequent milestone payments to Intrexon set forth in Sections
5.2(a)(i) through 5.2(a)(vi), shall be payable, at Intrexon’s option (and not Oragenics’ option), only in cash to Intrexon. 

(c)    Product Sublicense Milestones. If (A) a Commercialization Milestone Event occurs that gives rise
to a right for Intrexon to receive a payment from Oragenics under Section 5.2(a), (B) that Commercialization Milestone Event is achieved by an Oragenics Product licensed to a Product Sublicensee under a respective Product Sublicense, and
(C) Oragenics is due to receive a milestone payment from the Product Sublicensee for achievement of that same (or substantially similar) Commercialization Milestone Event by the sublicensed Oragenics Product under the respective Product
Sublicense, then Intrexon may elect at its own discretion to waive that particular milestone payment from Oragenics for that particular Commercialization Milestone Event and instead designate the amount of the payment due to Oragenics from the
Product Sublicensee for achievement of that same (or substantially similar) Commercialization Milestone Event as Sublicensing Revenue for which Intrexon will be entitled to receive revenue sharing under Section 5.4(b). If it so elects under
this Section 5.2(c), Intrexon must notify Oragenics in writing of its waiver of the equity-based milestone and election to share the milestone payment due from the Product Sublicensee as Sublicensing Revenue at least five (5) business days
prior to the deadline for Oragenics to make a payment for the waived milestone payment. The actual receipt by Intrexon of its full share of the Product Sublicensee milestone payment as Sublicensing Revenue will be a condition subsequent to making
final any waiver of Intrexon’s rights to receive the particular milestone payment otherwise due from Oragenics under Section 5.2(a). Oragenics will pay Intrexon any amount due under this Section 5.2(c) within the later of
(i) thirty (30) days from underlying Commercialization Milestone Event, or (ii) ten (10) days following the date stipulated in the underlying Product Sublicense for Oragenics to receive the milestone payment. 

(d)    Consolidation. The Parties agree that Oragenics’ option to pay any milestone payments that come
due for achievement of Commercialization Milestone Events under this Agreement in equity shall in no event require Intrexon to accept equity of Oragenics as payment if, upon Intrexon’s reasonable conclusion after consultation with its outside
advisors, receipt of such equity payment by Intrexon would cause Intrexon to have to consolidate Oragenics’ financial statements with Intrexon’s financial statements. To this end, upon each achievement of any Commercialization Milestone
Event that triggers a milestone payment being 

  
 27 

 
due by Oragenics to Intrexon under Section 5.2(a) above, Oragenics shall notify Intrexon as soon as possible if Oragenics intends to elect to pay the specific milestone payment in equity,
such notification being in writing and delivered to Intrexon in no event less than ten (10) business days from the date of achievement of the respective Commercialization Milestone Event. If Oragenics does not
so-notify Intrexon within the time frame set forth in the prior sentence, such specific Commercialization Milestone payment shall become payable to Intrexon solely in cash. Additionally, upon receiving any
notice from Oragenics under the second sentence of this Section 5.2(d) of Oragenics’ intent to pay a particular Commercialization Milestone payment in equity, Intrexon will therefrom have five (5) business days to consult with its
outside advisors to conclude whether the expected payment of Oragenics equity to Intrexon is reasonably likely to cause Intrexon to be required to consolidate Oragenics’ financial statements with its own. If Intrexon reasonably concludes, after
consultation with its outside advisors, that payment of the respective amount in Oragenics equity would cause consolidation, (i) Intrexon may notify Oragenics of this conclusion within such five (5) business days from Intrexon’s
receipt of Oragenics’ notice under this subsection, and (ii) upon Intrexon so-notifying Oragenics, the payment due for achievement of the respective Commercialization Milestone Event shall be payable
by Oragenics solely in cash, provided, however, that in the event Oragenics reasonably concludes that such cash payment would have an adverse effect on its working capital needs over the next twelve (12) months then such cash payment shall be
in the form of an interest bearing (under Section 5.9) promissory note with a maturity date of less than twelve (12) months and including other conventional market terms that would not be expected to unreasonably have an adverse effect on
Oragenics working capital needs over such next twelve (12) months. 
 5.3    Equity Agreement Controls.
All issuances of stock to Intrexon shall be in accordance with the terms and conditions of the Equity Agreement, which Equity Agreement shall control to the extent it may conflict with Sections 5.1 through 5.2 of this Agreement. 

5.4    Revenue Sharing. 

(a)    No later than thirty (30) days after each calendar quarter in which there is positive Net Sales arising
from the sale of any Oragenics Product in the Field in the Territory, Oragenics shall pay a royalty to Intrexon of twelve percent (12%) of such Net Sales, on an Oragenics
Product-by-Oragenics Product basis. Commencing with the Effective Date, in the event that no Net Sales occur for a particular Oragenics Product in any calendar quarter,
neither Oragenics nor Intrexon shall owe any payments hereunder with respect to such Oragenics Product. 

(b)    No later than thirty (30) days after each calendar quarter in which Oragenics or any Oragenics
Affiliate receives Sublicensing Revenue, Oragenics shall pay to Intrexon a percentage of such Sublicensing Revenue equal to the applicable Sublicensing Revenue Rate. 

(c)    Intrexon and Actobiotics shall be responsible for determining how any revenue sharing payments from
Oragenics due under Section 5.4(a) and 5.4(b) above are distributed among Intrexon and Actobiotics. 

  
 28 

 5.5    Method of Payment. Except for payments payable as
and made in the form of common stock, payments due to Intrexon under this Agreement shall be paid in United States dollars by wire transfer to a bank (or banks as otherwise set forth in Section 5.8) designated in writing by Intrexon. All
references to “dollars” or “$” herein shall refer to United States dollars. 

5.6    Payment Reports and Records Retention. Within thirty (30) days after the end of each calendar
quarter during which Net Sales have been generated, during which Sublicensing Revenue has been received, or during which a Commercialization Milestone Event has been achieved or a payment for such is made or due, Oragenics shall deliver to Intrexon
a written report that shall contain at a minimum for the applicable calendar quarter: 
 (a)    gross sales of
each Oragenics Product (on a country-by-country basis); 

(b)    itemized calculation of Net Sales, showing all applicable deductions and calculations; 

(c)    itemized calculation of Sublicensing Revenue, including any offsets claimed for Third Party license costs;

 (d)    the amount of the payment (if any) due pursuant to Section 5.4(a) and/or 5.4(b); 

(e)    the amount of the payment (if any) made or made due by the achievement of an applicable Commercialization
Milestone Event during the present calendar quarter; 
 (f)    the amount of taxes, if any, withheld to comply
with any applicable law; and 
 (g)    the exchange rates used in any of the foregoing calculations. 

For three (3) years after each sale or other commercial use of Oragenics Product, after incurring any component item Oragenics incorporated into its
calculation of Sublicensing Revenues, payments in accord with Section 5.2(b), or Net Sales as reported to Intrexon, Oragenics shall keep (and shall ensure that its Affiliates and, if applicable, (sub)licensees shall keep) complete and accurate
records of such sales, commercial use, or component item in sufficient detail to confirm the accuracy of the payment calculations hereunder. 

5.7    Audits. 

(a)    Upon the written request of Intrexon, Oragenics shall permit an independent certified public accounting firm
of internationally recognized standing selected by Intrexon, and reasonably acceptable to Oragenics, to have access to and to review, during normal business hours and upon no less than thirty (30) days prior written notice, the applicable
records of Oragenics and its Affiliates to verify the accuracy and timeliness of the reports and payments made by Oragenics under this Agreement. Such review may cover the records for sales made in any calendar year ending not more than three
(3) years prior to the date of such request. The accounting firm shall disclose to both Parties whether the royalty reports and/or know-how reports conform to the provisions of this Agreement and/or
US GAAP, as applicable, and the specific details concerning any discrepancies. Such audit may not be conducted more than once in any calendar year. 

  
 29 

 (b)    If such accounting firm concludes that additional amounts
were owed during such period, Oragenics shall pay additional amounts, with interest from the date originally due as set forth in Section 5.9, within thirty (30) days of receipt of the accounting firm’s written report. If the amount of
the underpayment is greater than five percent (5%) of the total amount actually owed for the period audited, then Oragenics shall in addition reimburse Intrexon for all costs related to such audit; otherwise, Intrexon shall pay all costs of the
audit. In the event of overpayment, any amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding calendar quarter(s); provided, however, that if such overpayment is reasonably expected
to exceed the amount projected to be payable to Intrexon by Oragenics over next two calendar quarters combined, Intrexon will promptly repay to Oragenics any amount exceeding that projected amount. 

(c)    Intrexon shall (i) treat all information that it receives under this Section 5.7 in accordance
with the confidentiality provisions of Article 7 and (ii) cause its accounting firm to enter into an acceptable confidentiality agreement with Oragenics obligating such firm to retain all such financial information in confidence pursuant to
such confidentiality agreement, in each case except to the extent necessary for Intrexon to enforce its rights under this Agreement. 

5.8    Taxes. The Parties will cooperate in good faith to obtain the benefit of any relevant tax treaties to
minimize as far as reasonably possible any taxes which may be levied on any amounts payable hereunder. Oragenics shall deduct or withhold from any payments any taxes that it is required by applicable law to deduct or withhold. Notwithstanding the
foregoing, if Intrexon is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding tax, it may deliver to Oragenics or the appropriate governmental authority (with the assistance of
Oragenics to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Oragenics of its obligation to withhold tax, and Oragenics
shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be, provided that Oragenics has received evidence of Intrexon’s delivery of all applicable forms (and, if necessary, its receipt of appropriate
governmental authorization) at least fifteen (15) days prior to the time that the payment is due. If, in accordance with the foregoing, Oragenics withholds any amount, it shall make timely payment to the proper taxing authority of the withheld
amount, and send to Intrexon proof of such payment within forty-five (45) days following that latter payment. Additionally, Intrexon may on an Oragenics
Product-by-Oragenics Product basis, and acting upon reasonable advice of outside tax and/or accounting advisors, request in writing that Oragenics make all of, or a
percentage of, any payment that becomes due under Section 5.2 or Section 5.4 above to Intrexon’s Affiliate directly (instead of to Intrexon), to the extent that such Affiliate has contributed intellectual property to the respective
Oragenics Product. To the extent that Oragenics has received such a request from Intrexon under the prior sentence at least thirty (30) days prior to the time that the payment is due, Oragenics shall honor the request to make the applicable
payments (in whole or in part, as applicable) to the Intrexon Affiliate. 

  
 30 

 5.9    Late Payments. Any amount owed by Oragenics to
Intrexon under this Agreement that is not paid within the applicable time period set forth herein shall accrue interest at the lower of (a) two percent (2%) per month, compounded, or (b) the highest rate permitted under applicable law.

 ARTICLE 6 

INTELLECTUAL PROPERTY 

6.1    Ownership. 

(a)    Subject to the license granted under Section 3.1, all rights in the Intrexon IP shall remain with
Intrexon. 
 (b)    Oragenics and/or Intrexon may solely or jointly conceive, reduce to practice or develop
discoveries, inventions, processes, techniques, and other technology, whether or not patentable, in the course of performing the Program (collectively “Inventions”). Each Party shall promptly provide the other Party with a detailed
written description of any such Inventions that relate to the Field. Inventorship shall be determined in accordance with United States patent laws. 

(c)    Intrexon shall solely own all right, title and interest in all Inventions related to Intrexon Channel
Technology, together with all Patent rights and other intellectual property rights therein (the “Channel-Related Program IP”). Oragenics hereby assigns all of its right, title and interest in and to the Channel-Related Program IP to
Intrexon. Oragenics agrees to execute such documents and perform such other acts as Intrexon may reasonably request to obtain, perfect and enforce its rights to the Channel-Related Program IP and the assignment thereof. 

(d)    Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or
other technology, whether or not patentable, that is conceived, reduced to practice or developed by Oragenics solely or jointly through the use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of the terms and
conditions of this Agreement, together with all patent rights and other intellectual property rights therein, shall be solely owned by Intrexon and shall be included in the Channel-Related Program IP. 

(e)    All Information regarding Channel-Related Program IP shall be Confidential Information of Intrexon.
Oragenics shall be under appropriate written agreements with each of its employees, contractors, or agents working on the Program, pursuant to which such person shall grant all rights in the Inventions to Oragenics (so that Oragenics may convey
certain of such rights to Intrexon, as provided herein) and agree to protect all Confidential Information relating to the Program. 

(f)    All rights, technology, and intellectual property (A) owned by Oragenics or licensed from a Third Party
by Oragenics as of the Effective Date, or (B) thereafter developed by Oragenics independent of the Program, Actobiotics IP, Intrexon Channel Technology, Intrexon IP or Intrexon Materials, shall be owned by and remain the property of Oragenics
(the “Oragenics Independent IP”). 

  
 31 

 6.2    Patent Prosecution. 

(a)    Intrexon shall have the sole right, but not the obligation, to (a) conduct and control the filing,
prosecution and maintenance of the Intrexon Patents, and (b) conduct and control the filing, prosecution, and maintenance of any applications for patent term extension and/or supplementary protection certificates for the Intrexon Patents that
may be available as a result of the regulatory approval of any Oragenics Product. At the reasonable request of Intrexon, Oragenics shall cooperate with Intrexon in connection with such filing, prosecution, and maintenance, at Intrexon’s
expense. Under no circumstances shall Oragenics (a) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application, either in the United States or elsewhere, that claims or uses or purports to claim or use
or relies for support upon an Invention owned by Intrexon, (b) use, attempt to use, or assist anyone else in using or attempting to use, the Intrexon Know-How, Intrexon Materials, or any Confidential
Information of Intrexon to support the filing of a Patent application, either in the United States or elsewhere, that contains claims directed to the Intrexon IP, Intrexon Materials, or the Intrexon Channel Technology, or (c) without prior
approval of the IPC, file, attempt to file, or assist anyone else in filing, or attempting to file, any application for patent term extension or supplementary protection certificate, either in the United States or elsewhere, that relies upon the
regulatory approval of an Oragenics Product. 
 (b)    Oragenics shall have the sole right, but not the
obligation, to conduct and control the filing, prosecution and maintenance of any Patents claiming Inventions that are owned by Oragenics or its Affiliates and not assigned to Intrexon under Section 6.1(c) (“Oragenics Program
Patents”). At the reasonable request of Oragenics, Intrexon shall cooperate with Oragenics in connection with such filing, prosecution, and maintenance, at Oragenics’ expense. 

(c)    As used herein, “Prosecuting Party” means Intrexon in the case of Intrexon Patents and
Oragenics in the case of Oragenics Program Patents. The Prosecuting Party shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including in-house patent counsel as well as outside patent counsel) for the prosecution of the Intrexon Patents and Oragenics Program Patents, as applicable. The Prosecuting Party shall: 

(i)    regularly provide the other Party in advance with reasonable information relating to the Prosecuting Party’s
prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and copies of drafts of filings and correspondence that the Prosecuting
Party proposes to submit to such patent authorities (it being understood that, to the extent that any such information is readily accessible to the public, the Prosecuting Party may, in lieu of directly providing copies of such information to such
other Party, provide such other Party with sufficient information that will permit such other Party to access such information itself directly); 

  
 32 

 (ii)    consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; provided, however, that if, within fifteen (15) days after providing any documents to the
non-Prosecuting Party for comment, the Prosecuting Party does not receive any written communication from the non-Prosecuting Party indicating that it has or may have
comments on such document, the Prosecuting Party shall be entitled to assume that the non-Prosecuting Party has no comments thereon; 

(iii)    consult with the non-Prosecuting Party before taking any action that
would reasonably be expected to have a material adverse impact on the scope of claims within the Intrexon Patents and Oragenics Program Patents, as applicable. 

6.3    Infringement of Patents by Third Parties. 

(a)    Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to
take appropriate action against any person or entity directly or indirectly infringing any Intrexon Patent (or asserting that an Intrexon Patent is invalid or unenforceable) (collectively, “Infringement”), either by settlement or
lawsuit or other appropriate action. 
 (b)    Notwithstanding the foregoing, Oragenics shall have the first
right, but not the obligation, to take appropriate action to enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly infringing activities in the Field (“Field
Infringement”), either by settlement or lawsuit or other appropriate action. If Oragenics exercises the foregoing right, Intrexon agrees to be named in any such action if required. If Oragenics fails to take the appropriate steps to enforce
Product-Specific Program Patents against any Field Infringement within one hundred eighty (180) days of the date one Party has provided notice to the other Party pursuant to Section 6.3(g) of such Field Infringement, then Intrexon shall
have the right (but not the obligation), at its own expense, to enforce Product-Specific Program Patents against such Field Infringement, either by settlement or lawsuit or other appropriate action. 

(c)    With respect to any Field Infringement that cannot reasonably be abated through the enforcement of
Product-Specific Program Patents pursuant to Section 6.3(b) but can reasonably be abated through the enforcement of Intrexon Patent(s) (other than the Product-Specific Program Patents), Intrexon shall be obligated to choose one of the following
courses of action: (i) enforce one or more of the applicable Intrexon Patent(s) in a commercially reasonable manner against such Field Infringement, or (ii) enable Oragenics to do so directly. The Party enforcing the applicable Intrexon
Patent(s) shall bear the costs and expenses of such enforcement. The determination of which Intrexon Patent(s) to assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall consult in good faith with Oragenics on
such determination. For the avoidance of doubt, Intrexon has no obligations under this Agreement to enforce any Intrexon Patents against, or otherwise abate, any Infringement that is not a Field Infringement. 

(d)    In the event a Party pursues an action under this Section 6.3, the other Party shall reasonably
cooperate with the enforcing Party with respect to the investigation and prosecution of any alleged, threatened, or actual Infringement, at the enforcing Party’s expense. 

  
 33 

 (e)    Oragenics shall not settle or otherwise compromise any
action under this Section 6.3 in a way that diminishes the rights or interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon’s prior written consent, which consent shall not be unreasonably
withheld. Intrexon shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights or interests of Oragenics in the Field or adversely affects any Intrexon Patent with respect to the Field without
Oragenics’ prior written consent, which consent shall not be unreasonably withheld. 
 (f)    Except as
otherwise agreed to by the Parties in writing, any settlements, damages or other monetary awards recovered pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of the Party
controlling such action, and second, to the costs and expenses (if any) of the other Party (to the extent not otherwise reimbursed), and any remaining amounts (the “Recovery”) will be shared by the Parties as follows:
In any action initiated by Intrexon pursuant to Section 6.3(a) that does not involve Field Infringement, or in any action initiated by Intrexon pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery.
In any action initiated by Oragenics pursuant to Section 6.3(b), Oragenics shall retain one hundred percent (100%) of any Recovery, but such Recovery shall be shared with Intrexon as Sublicensing Revenue. In any action initiated by Intrexon or
Oragenics pursuant to Section 6.3(c), the enforcing Party shall retain one hundred percent (100%) of any Recovery. 

(g)    Oragenics shall promptly notify Intrexon in writing of any suspected, alleged, threatened, or actual
Infringement of which it becomes aware, and Intrexon shall promptly notify Oragenics in writing of any suspected, alleged, threatened, or actual Field Infringement of which it becomes aware. 

ARTICLE 7 

CONFIDENTIALITY 

7.1    Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in
writing by the Parties, each Party agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement any Confidential Information disclosed to it by the
other Party pursuant to this Agreement, except to the extent that the receiving Party can demonstrate by competent evidence that specific Confidential Information: 

(a)    was already known to the receiving Party, other than under an obligation of confidentiality, at the time of
disclosure by the other Party; 
 (b)    was generally available to the public or otherwise part of the public
domain at the time of its disclosure to the receiving Party; 
 (c)    became generally available to the public
or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 

  
 34 

 (d)    was disclosed to the receiving Party, other than under an
obligation of confidentiality to a Third Party, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or 

(e)    was independently discovered or developed by the receiving Party without the use of Confidential Information
belonging to the disclosing Party, as documented by the receiving Party’s written records. 
 The foregoing non-use and non-disclosure obligation shall continue (i) indefinitely, for all Confidential Information that qualifies as a trade secret under applicable law; or
(ii) for the Term of this Agreement and for seven (7) years thereafter, in all other cases. 

7.2    Authorized Disclosure. Notwithstanding the limitations in this Article 7, either Party may disclose
the Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 

(a)    complying with applicable laws or regulations or valid court orders, provided that the Party making
such disclosure provides the other Party with reasonable prior written notice of such request or demand for disclosure and makes a reasonable effort to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the
disclosure and/or requiring that the terms and conditions of this Agreement be used only for the purposes for which the law or regulation required, or for which the order was issued; 

(b)    to regulatory authorities in order to seek or obtain approval to conduct clinical trials, or to gain
regulatory approval, of Oragenics Products or any products being developed by Intrexon or its other licensees and/or channel partners or collaborators, provided that the Party making such disclosure (i) provides the other Party with reasonable
opportunity to review any such disclosure in advance and to suggest redactions or other means of limiting the disclosure of such other Party’s Confidential Information and (ii) does not unreasonably reject any such suggestions; 

(c)    disclosure to investors and potential investors, acquirers, or merger candidates who agree to maintain the
confidentiality of such information, provided that such disclosure is used solely for the purpose of evaluating such investment, acquisition, or merger (as the case may be); 

(d)    disclosure on a need-to-know
basis to Affiliates, licensees, sublicensees, employees, consultants or agents (such as CROs and clinical investigators) who agree to be bound by obligations of confidentiality and non-use at least equivalent
in scope to those set forth in this Article 7; and 
 (e)    disclosure of the terms of this Agreement by
Intrexon to collaborators and other channel partners or collaborators who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7. 

7.3    Publicity; Publications. The Parties agree that the public announcement of the execution of this
Agreement shall be substantially in the form of a press release (the form of which shall be mutually agreed to by the Parties) and/or the filing of a Form 8-K by one or both

  
 35 

 
of the Parties (to the extent required by relevant laws or regulations relating to required disclosure of material information to public markets and/or the SEC). Each Party will provide the other
Party with the opportunity to review and comment, prior to submission or presentation, on external reports, securities filings, publications and presentations (e.g., press releases, reports to government agencies, abstracts, posters, manuscripts and
oral presentations) that refer to the Program, Oragenics Products, or programs that are approved by the JSC. For such reports, publications, and presentations, the disclosing Party will provide the other Party at least fifteen (15) calendar
days for review of the proposed submission or presentation. In the case of a Form 8-K filing, such shall be provided to the non-filing Party by the filing party as soon
as practicable prior to filing for review and comment. For reports and manuscripts, the disclosing Party will provide the other Party at least thirty (30) days for review of the report or manuscript. The presenting Party will act in good faith
to incorporate the comments of the other Party and shall, in any event, redact any Confidential Information of the other Party and cooperate with the other Party to postpone such submissions or presentations if necessary to provide the other Party
with sufficient time to prepare and file any related Patent applications before the submission or presentation occurs, as appropriate. 

7.4    Terms of the Agreement. Each Party shall treat the terms of this Agreement as the Confidential
Information of other Party, subject to the exceptions set forth in Section 7.2. Notwithstanding the foregoing, each Party acknowledges that the other Party may be obligated to file a copy of this Agreement with the SEC, either as of the
Effective Date or at some point during the Term. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of certain commercial terms and sensitive technical terms hereof to the extent such
confidential treatment is reasonably available to it. In the event of any such filing, the filing Party shall provide the other Party with a copy of the Agreement marked to show provisions for which the filing Party intends to seek confidential
treatment and shall reasonably consider and incorporate the other Party’s comments thereon to the extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed. The other
Party shall promptly provide any such comments. 
 7.5    Proprietary Information and Operational Audits. 

(a)    For the purpose of confirming compliance with the Field-limited licenses granted in Article 3, the diligence
obligations of Article 4, and the confidentiality obligations under Article 7, Oragenics acknowledges that Intrexon’s authorized representative(s), during regular business hours may (i) examine and inspect Oragenics’ facilities and
(ii) inspect all data and work products relating to this Agreement, subject to restrictions imposed by applicable laws. Any examination or inspection hereunder shall require five (5) business days written notice from Intrexon to Oragenics.
Oragenics will make itself and the pertinent employees and/or agents available, on a reasonable basis, to Intrexon for the aforementioned compliance review. 

(b)    For the purpose of confirming compliance with the diligence obligations of Section 4.6, and the
confidentiality obligations under Article 7, Intrexon acknowledges that Oragenics authorized representative(s), during regular business hours may (i) examine and inspect Intrexon’s facilities and (ii) inspect all data and work
products relating to this Agreement. Any examination or inspection hereunder shall require five (5) business days written notice from Oragenics to Intrexon. Intrexon will make itself and the pertinent employees and/or agents available, on a
reasonable basis, to Oragenics for the aforementioned compliance review. 

  
 36 

 (c)    In view of the Intrexon Confidential Information, Intrexon
Know-How, and Intrexon Materials transferred to Oragenics hereunder, Intrexon from time-to-time, but no more than quarterly, may
request that Oragenics confirm the status of the Intrexon Materials at Company (i.e. how much used, how much shipped, to whom and any unused amounts destroyed (by whom, when) as well as any amounts returned to Intrexon or destroyed). Within ten
(10) business days of Oragenics’ receipt of any such written request, Oragenics shall provide the written report to Intrexon. 

7.6    Intrexon and Actobiotics Commitment. Intrexon and Actobiotics shall use reasonable efforts to obtain
an agreement with its other licensees and channel partners or collaborators to enable Oragenics to disclose confidential information of such licensees and channel partners or collaborators to regulatory authorities in order to seek or obtain
approval to conduct clinical trials, or to gain regulatory approval of, Oragenics Products, in a manner consistent with the provisions of Section 7.2(b). 

ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1    Representations and Warranties of Oragenics. Oragenics hereby represents and warrants to Intrexon and
Actobiotics that, as of the Effective Date: 
 (a)    Corporate Power. Oragenics is duly organized and
validly existing under the laws of Florida and has corporate full power and authority to enter into this Agreement and to carry out the provisions hereof. 

(b)    Due Authorization. Oragenics is duly authorized to execute and deliver this Agreement and to perform
its obligations hereunder, and the person executing this Agreement on Oragenics’ behalf has been duly authorized to do so by all requisite corporate action. 

(c)    Binding Agreement. This Agreement is a legal and valid obligation binding upon Oragenics and
enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to general equity
principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Oragenics does not conflict with any agreement, instrument or understanding, oral or
written, to which it is a party or by which it may be bound. Oragenics is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement. 

  
 37 

 8.2    Representations and Warranties of Intrexon and
Actobiotics. Intrexon and Actobiotics hereby represent and warrant to Oragenics that, as of the Effective Date: 

(a)    Corporate Power. Intrexon and Actobiotics are duly organized and validly existing under the laws of
the jurisdiction of its organization and have full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 

(b)    Due Authorization. Intrexon and Actobiotics are duly authorized to execute and deliver this Agreement
and to perform its obligations hereunder, and the person executing this Agreement on Intrexon’s and Actobiotics’s behalf has been duly authorized to do so by all requisite corporate action. 

(c)    Binding Agreement. This Agreement is a legal and valid obligation binding upon Intrexon and
Actobiotics and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to
general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Intrexon and Actobiotics does not conflict with any agreement, instrument
or understanding, oral or written, to which it is a party or by which it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this
Agreement. 
 (d)    Additional Intellectual Property Representations. 

(i)    Intrexon and Actobiotics possesses sufficient rights to enable them to grant all rights and licenses it purports to
grant to Oragenics with respect to the Intrexon IP and Actobiotics IP under this Agreement; 
 (ii)    The Intrexon IP
and the Actobiotics IP existing as of the Effective Date constitute all of the intellectual property Controlled by Intrexon and Actobiotics as of such date that is necessary for the development, manufacture or Commercialization of Oragenics
Products; 
 (iii)    Intrexon and Actobiotics have not granted, and during the Term Intrexon and Actobiotics will not
grant, any right or license, to any Third Party under the Intrexon IP and Actobiotics IP that conflicts with the rights or licenses granted or to be granted to Oragenics hereunder 

(iv)    There is no pending litigation, and neither Intrexon nor Actobiotics has received any written notice of any
claims or litigation, seeking to invalidate or otherwise challenge the Intrexon IP or Intrexon’s rights therein or the Actobiotics IP or Actobiotics’s rights therein; 

(v)    None of the Intrexon IP or Actobiotics IP is subject to any pending
re-examination, opposition, interference or litigation proceedings; 

(vi)    All of the Intrexon Patents and Actobiotics Patents have been filed and prosecuted in accordance with all
applicable laws and have been maintained, with all applicable fees with respect thereto (to the extent such fees have come due) having been paid; 

  
 38 

 (vii)    Intrexon and Actobiotics have entered into agreements with
each of its current and former officers, employees and consultants involved in research and development work, including development of the Intrexon’s and Actobiotics’s products and technology providing Intrexon and Actobiotics, to the
extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with other of such persons, during the period of employment
by or contract with Intrexon or Actobiotics (except where the failure to have entered into such an agreement would not have a material adverse effect on the rights granted to Oragenics herein), and neither Intrexon nor Actobiotics is aware that any
of its employees or consultants is in material violation thereof; 
 (viii)    To Intrexon’s and/or
Actobiotics’s knowledge, there is no infringement, misappropriation or violation by Third Parties of any Intrexon Channel Technology, Intrexon IP, or Actobiotics IP in the Field; 

(ix)    There is no pending or, to Intrexon’s and/or Actobiotics’s knowledge, threatened action, suit,
proceeding or claim by others against Intrexon that Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with the use of the Intrexon Channel Technology, Intrexon IP,
and Actobiotics IP, and neither Intrexon nor Actobiotics has received any written notice of such claim; 
 (x)    To
Intrexon’s and/or Actobiotics’s knowledge, no employee of Intrexon or Actobiotics is the subject of any claim or proceeding involving a violation of any term of any employment contract, patent disclosure agreement, invention assignment
agreement, non-competition agreement, non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with
a former employer (A) where the basis of such violation relates to such employee’s employment with Intrexon or Actobiotics or actions undertaken by the employee while employed with Intrexon or Actobiotics and (B) where such violation
is relevant to the use of the Intrexon Channel Technology or Actobiotics IP in the Field; 
 (xi)    None of the
Patents in the Actobiotics IP or Intrexon IP, and, to Intrexon’s and/or Actobiotics’s knowledge, none of the Patents licensed in the Actobiotics IP or Intrexon IP to Intrexon or its Affiliates, have been adjudged invalid or unenforceable
by a court of competent jurisdiction or applicable government agency, in whole or in part, and there is no pending or, to Intrexon’s and/or Actobiotics’s knowledge, threatened action, suit, proceeding or claim by others challenging the
validity or scope of any such Intrexon Patents; and 
 (xii)    Except as otherwise disclosed in writing to Oragenics,
Intrexon and Actobiotics: (A) are in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale,
offer for sale, storage, import, export or disposal of any product that is under development, manufactured or distributed by Intrexon and Actobiotics in the Field (“Applicable Laws”); (B) has not received any FDA Form 483, notice of
adverse finding, warning letter, untitled letter or other correspondence or notice from the United States Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority
alleging or asserting material noncompliance with any 

  
 39 

 
Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws
(“Authorizations”), which would, individually or in the aggregate, result in a material adverse effect; (C) possesses all material Authorizations necessary for the operation of its business as described in the Field and such
Authorizations are valid and in full force and effect and Intrexon is not in material violation of any term of any such Authorizations; and (D) since January 1, 2011, (1) has not received notice of any claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation
of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit
investigation or proceeding; (2) has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any
material Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such action; (3) has filed, obtained, maintained or submitted all material reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (4) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused
to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any
alleged product defect or violation and, to Intrexon’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action 

(xiii)    Prior to the Effective Date, Intrexon and Actobiotics have provided Oragenics with copies of all material
correspondence, communications, and filings with the FDA and other regulatory authorities regarding AG013 and its pre-clinical and clinical testing, and associated underlying reports and data. 

except, in each of (ix) through (xiii), for any instances which would not, individually or in the aggregate, result in a material adverse effect on the
rights granted to Oragenics hereunder or Intrexon’s or Actobiotics’s ability to perform its obligations hereunder. 

8.3    Warranty Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS ARTICLE 8 OR IN THE EQUITY
AGREEMENT, EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY
RIGHTS OF THIRD PARTIES. 

  
 40 

 ARTICLE 9 

INDEMNIFICATION 

9.1    Indemnification by Intrexon. Intrexon agrees to indemnify, hold harmless, and defend Oragenics and
its Affiliates and their respective directors, officers, employees, and agents (collectively, the “Oragenics Indemnitees”) from and against any and all liabilities, damages, costs, expenses, or losses (including reasonable legal
expenses and attorneys’ fees) (collectively, “Losses”) resulting from any claims, suits, actions, demands, or other proceedings brought by a Third Party (collectively, “Claims”) to the extent arising from
(a) the negligence or willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents, (b) the use, handling, storage or transport of Intrexon Materials or materials that are Actobiotics IP, by Intrexon or
its Affiliates, licensees (other than Oragenics) or sublicensees; or (c) breach by Intrexon or Actobiotics of any representation, warranty or covenant in this Agreement. Notwithstanding the foregoing, Intrexon shall not have any obligation to
indemnify the Oragenics Indemnitees to the extent that a Claim arises from (i) the negligence or willful misconduct of Oragenics or any of its Affiliates, licensees, or sublicensees, or their respective employees or agents; or (ii) a
breach by Oragenics of a representation, warranty, or covenant of this Agreement. 
 9.2    Indemnification by
Oragenics. Oragenics agrees to indemnify, hold harmless, and defend Intrexon, its Affiliates and Third Security, and their respective directors, officers, employees, and agents (and any Third Parties which have licensed to Intrexon intellectual
property rights within Intrexon IP on or prior to the Effective Date, to the extent required by the relevant upstream license agreement) (collectively, the “Intrexon Indemnitees”) from and against any Losses resulting from Claims,
to the extent arising from any of the following: (a) the negligence or willful misconduct of Oragenics or any of its Affiliates or their respective employees or agents; (b) the use, handling, storage, or transport of Intrexon Materials or
materials that are Actobiotics IP by Oragenics or its Affiliates, licensees, or sublicensees; (c) breach by Oragenics of any material representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture,
regulatory approval, handling, storage, transport, distribution, sale or other disposition of any Oragenics Product by Oragenics or its Affiliates, licensees, or sublicensees. Notwithstanding the foregoing, Oragenics shall not have any obligation to
indemnify the Intrexon Indemnitees to the extent that a Claim arises from (i) the negligence or willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents; or (ii) a breach by Intrexon of a
representation, warranty, or covenant of this Agreement. 
 9.3    Product Liability Claims.
Notwithstanding the provisions of Section 9.2, any Losses arising out of any Third Party claim, suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising out of or resulting from the
development, manufacture or Commercialization of any Oragenics Products for use or sale in the Field, to the extent that such Losses exceed the amount (if any) covered by the applicable Party’s product liability insurance (“Excess
Product Liability Costs”), shall be paid by Oragenics, except to the extent such Losses arise out of any Third-Party Claim based on the gross negligence or willful misconduct of a Party, its Affiliates, or its Affiliates’ sublicensees,
or any of the respective officers, directors, employees and agents of each of the foregoing entities, in the performance of obligations or exercise of rights under this Agreement. 

  
 41 

 9.4    Control of Defense. As a condition precedent to any
indemnification obligations hereunder, any entity entitled to indemnification under this Article 9 shall give written notice to the indemnifying Party of any Claims that may be subject to indemnification, promptly after learning of such Claim. If
such Claim falls within the scope of the indemnification obligations of this Article 9, then the indemnifying Party shall assume the defense of such Claim with counsel reasonably satisfactory to the indemnified Party. The indemnified Party shall
cooperate with the indemnifying Party in such defense. The indemnified Party may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to such Claim. The indemnifying Party shall not be liable
for any litigation costs or expenses incurred by the indemnified Party without the indemnifying Party’s written consent, such consent not to be unreasonably withheld. The indemnifying Party shall not settle any such Claim if such settlement
(a) does not fully and unconditionally release the indemnified Party from all liability relating thereto or (b) adversely impacts the exercise of the rights granted to the indemnified Party under this Agreement, unless the indemnified
Party otherwise agrees in writing. 
 9.5    Insurance. Immediately prior to, and during marketing of
Oragenics Products, Oragenics shall maintain, and shall cause its permitted sublicensees to maintain, in effect and good standing a product liability insurance policy issued by a reputable insurance company in amounts considered standard for the
industry. Immediately prior to, and during the conduct of any clinical trials, Oragenics shall maintain, and shall cause any relevant permitted sublicensees to maintain, in effect and good standing a clinical trials liability insurance policy issued
by a reputable insurance company in amounts considered standard for the industry. At Intrexon’s reasonable request, Oragenics shall provide Intrexon with all details regarding such policies, including without limitation copies of the applicable
liability insurance contracts. Oragenics shall use reasonable efforts to include Intrexon as an additional insured on any such policies. 

ARTICLE 10 

TERM; TERMINATION 

10.1    Term. The term of this Agreement shall commence upon the Effective Date and shall continue until
terminated pursuant to Section 10.2 or 10.3 (the “Term”). 
 10.2    Termination for Material
Breach; Termination Under Section 4.5(b) 
 (a)    Either Party shall have the right to terminate this
Agreement upon written notice to the other Party if the other Party commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the
non-breaching Party specifying such breach, provided, however, that solely for purposes of Section 9.5 the cure period shall be ninety (90) days. 

(b)    Intrexon shall have the right to terminate this Agreement, at its sole discretion, if the Technology Access
Fee has not been paid in accordance with the terms and conditions of this Agreement and the Equity Agreement, including if the full principal on the Note (as defined in the Equity Agreement) has not been paid within the timeframes set forth in the
Note (including the issuance to Intrexon of any shares in payment thereof). 

  
 42 

 (c)    Intrexon shall have the right to terminate this Agreement
under the circumstances set forth in Section 4.5(b) upon written notice to Oragenics, such termination to become effective sixty (60) days following such written notice unless Oragenics remedies the circumstances giving rise to such
termination within such sixty (60) day period. 
 (d)     Intrexon shall have the right to terminate this
Agreement should Oragenics execute any purported assignment of this Agreement contrary to the prohibitions in Section 12.8, such termination occurring upon Intrexon providing written notice to Oragenics and becoming effective immediately upon
such written notice. 
 (e)    Intrexon hereby acknowledges that Oragenics will need to raise additional capital
in order to carry out its obligations under this Agreement and during the sixteen (16) month period commencing on the Effective Date (the “Initial Financing Period”) Intrexon shall not have the right during the Initial
Financing Period (i) to terminate this Agreement under Section 10.2(a) based on the failure of a Party to use Diligent Efforts or to comply with any other diligence obligations hereunder (including Section 4.5), or (ii) to
terminate this Agreement under Section 10.2(c). Notwithstanding the foregoing, (i) the Parties shall pursue the Initial Study in accord with the terms and conditions of this Agreement with Diligent Efforts during the Initial Financing
Period, and (ii) the Parties, for clarity, shall only be absolved of failing to advance the Program (other than the Initial Study) with Diligent Efforts during the Initial Financing Period to the extent that any such failure to use Diligent
Efforts is due to Oragenics working capital and financing considerations. Additionally, Intrexon agrees to reasonably cooperate to assist Oragenics in its undertaking to seek financing during the Initial Financing Period, and agrees to participate
in any financing to the extent necessary for Oragenics to obtain financing necessary to support Program activities during the Initial Financing Period (including for the Initial Study) up to the lesser of (i) the amount of Intrexon’s pro
rata equity holdings in Oragenics as of the Effective Date, and (ii) ten million United States dollars($10,000,000) total. Notwithstanding the foregoing, Intrexon’s agreement to participate in financing under the prior sentence shall not
obligate Intrexon to participate in any such financing to the extent that such financing occurs or closes after a Reverse Merger. 

10.3    Termination by Oragenics. Following the full payment of the Technology Access Fee to Intrexon in
full satisfaction of the terms of the Equity Agreement, Oragenics shall have the right to voluntarily terminate this Agreement in its entirety upon ninety (90) days written notice to Intrexon. 

10.4    Effect of Termination. In the event of termination of this Agreement pursuant to Section 10.2
or Section 10.3, the following shall apply: 
 (a)    Retained Products. Oragenics shall be permitted
to continue the clinical development and Commercialization in the Field of any product resulting from the Program that, at the time of any termination, satisfies at least one of the following criteria (a “Retained Product”): 

(i)    the particular product is an Oragenics Product that is being sold by Oragenics (or, as may be permitted in accord
with this Agreement, its Affiliates or sublicensees) triggering profit sharing payments therefor under Sections 5.4(a) or 5.4(b) of this Agreement, 

  
 43 

 (ii)    the particular product is an Oragenics Product has received
regulatory approval, 
 (iii)    the particular product is an Oragenics Product that is the subject of an application
for regulatory approval in the Field that is pending before the applicable regulatory authority, 
 (iv)    the
particular product is the specific Oragenics Product AG013, and such Oragenics Product has been the subject of at least one completed phase II clinical trial (as such is defined by relevant FDA guidelines) during the Term, or 

(v)    the particular product is an Oragenics Product other than AG013, and such Oragenics Product is the subject of at
least an ongoing phase I, phase II or phase III clinical trial in the Field (in the case of a termination by Intrexon due to an Oragenics uncured breach pursuant to Section 10.2(a) or a termination by Oragenics pursuant to Section 10.3).

 Such rights to continue development and Commercialization under this Section 10.4(a) shall be subject to Oragenics’ full compliance with the
payment provisions in Article 5, a continuing obligation for Oragenics to use in accord with Sections 4.5(a) and 4.5(c) Diligent Efforts to develop and Commercialize any Retained Products, and all other provisions of this Agreement that survive
termination. 
 (b)    Termination of Licenses. Except as necessary for Oragenics to continue to obtain
regulatory approval for, clinically develop, use, manufacture and Commercialize the Retained Products in the Field as permitted by Section 10.4(a), all rights and licenses granted by Intrexon to Oragenics under this Agreement shall terminate
and shall revert to Intrexon without further action by either Intrexon or Oragenics. Oragenics’ license with respect to Retained Products shall be exclusive or non-exclusive, as the case may be, on the
same terms as set forth in Section 3.1. 
 (c)    Reverted Products. All Oragenics Products other
than the Retained Products shall be referred to herein as the “Reverted Products.” Oragenics shall immediately cease, and shall cause its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and
Commercialization of the Reverted Products, and Oragenics shall not use or practice, nor shall it cause or permit any of its Affiliates or, if applicable, (sub)licensees to use or practice, directly or indirectly, any Intrexon IP with respect to the
Reverted Products. Oragenics shall immediately discontinue making any representation regarding its status as a licensee or channel collaborator of Intrexon with respect to the Reverted Products. 

(d)    Intrexon Materials. Oragenics shall promptly return, or at Intrexon’s request, destroy, any
Intrexon Materials in Oragenics’ possession or control at the time of termination other than any Intrexon Materials necessary for the continued development, regulatory approval, use, manufacture and Commercialization of the Retained Products in
the Field. 

  
 44 

 (e)    Licenses to Intrexon. Oragenics is automatically
deemed to grant to Intrexon a worldwide, fully paid, royalty-free, exclusive (even as to Oragenics and its Affiliates), irrevocable, license (with full rights to sublicense) under the Oragenics Termination IP, to make, have made, import, use, offer
for sale and sell Reverted Products and to use the Intrexon Channel Technology, the Intrexon Materials, and/or the Intrexon IP in the Field, subject to any exclusive rights held by Oragenics in Reverted Products pursuant to Section 10.4(c). The
Parties shall also take such actions and execute such other instruments and documents as may be reasonably necessary to document such license to Intrexon. 

(f)    Regulatory Filings. Oragenics shall promptly assign to Intrexon, and will provide full copies of, all
regulatory approvals and regulatory filings that relate specifically and solely to Reverted Products. Oragenics shall also take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of
rights thereunder to Intrexon. To the extent that there exist any regulatory approvals and regulatory filings that relate both to Reverted Products and other products, Oragenics shall provide copies of the portions of such regulatory filings that
relate to Reverted Products and shall reasonably cooperate to assist Intrexon in obtaining the benefits of such regulatory approvals with respect to the Reverted Products. 

(g)    Data Disclosure. Oragenics shall provide to Intrexon copies of the relevant portions of all material
reports and data, including clinical and non-clinical data and reports, obtained or generated by or on behalf of Oragenics or its Affiliates to the extent that they relate to Reverted Products, within sixty
(60) days of such termination unless otherwise agreed, and Intrexon shall have the right to use any such Information in developing and Commercializing Reverted Products and to license any Third Parties to do so. 

(h)    Third-Party Licenses. At Intrexon’s request, Oragenics shall promptly provide to Intrexon copies
of all Third-Party agreements under which Oragenics or its Affiliates obtained a license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture
and/or Commercialization of the Reverted Products. At Intrexon’s request such that Intrexon may Commercialize the Reverted Products, Oragenics shall promptly work with Intrexon to either, as appropriate, (A) assign to Intrexon the Third
Party agreement(s), or (B) grant a sublicense (with an appropriate scope) to Intrexon under the Third Party agreement(s). Thereafter Intrexon shall be fully responsible for all obligations due for its actions under the sublicensed or assigned
Third Party agreements. Notwithstanding the above, if Intrexon does not wish to assume any financial or other obligations associated with a particular Third Party agreement identified to Intrexon under this Section 10.4(h), then Intrexon shall
so notify Oragenics and Oragenics shall not make such assignment or grant such sublicense (or cause it to be made or granted). 

(i)    Remaining Materials. At the request of Intrexon, Oragenics shall transfer to Intrexon all quantities
of Reverted Product (including final products or work-in-process) in the possession of Oragenics or its Affiliates. Oragenics shall transfer to Intrexon all such
quantities of Reverted Products without charge, except that Intrexon shall pay the reasonable costs of shipping. 

  
 45 

 (j)    Third Party Vendors. At Intrexon’s request,
Oragenics shall promptly provide to Intrexon copies of all agreements between Oragenics or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply, sale, or distribution of Reverted Products in the Territory. At
Intrexon’s request, Oragenics shall promptly: (A) with respect to such Third Party agreements relating solely to the applicable Reverted Products and permitting assignment, immediately assign (or cause to be assigned), such agreements to
Intrexon, and (B) with respect to all other such Third Party agreements, Oragenics shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. Oragenics shall be liable for any costs associated with assigning a
Third Party agreement to Intrexon or otherwise obtaining the benefits of such agreement for Intrexon, to the extent such costs are directly related to Oragenics’ breach. For the avoidance of doubt, Intrexon shall have no obligation to assume
any of Oragenics’ obligations under any Third Party agreement. 
 (k)    Commercialization. Intrexon
shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Oragenics, to take any such actions in connection with such activities as Intrexon (or
its designee), at its discretion, deems appropriate. 
 (l)    Confidential Information. Each Party shall
promptly return, or at the other Party’s request destroy, any Confidential Information of the other Party in such Party’s possession or control at the time of termination; provided, however, that each Party shall be permitted to retain
(i) a single copy of each item of Confidential Information of the other Party in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii) Confidential Information of the other Party that
is maintained as archive copies on the recipient Party’s disaster recovery and/or information technology backup systems, or (iii) Confidential Information of the other Party necessary to exercise such Party’s rights in Retained
Products (in the case of Oragenics) or Reverted Products (in the case of Intrexon). The recipient of Confidential Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information
retained in accordance with this Section 10.4(l). 
 10.5    Surviving Obligations. Termination or
expiration of this Agreement shall not affect any rights of either Party arising out of any event or occurrence prior to termination, including, without limitation, any obligation of Oragenics to pay any amount which became due and payable under the
terms and conditions of this Agreement prior to expiration or such termination. The following portions of this Agreement shall survive termination or expiration of this Agreement: Sections 3.1 (as applicable with respect to 10.4(b), 5.5, 5.7 (only
as to any pre-termination period), 6.1, 6.2 (with subsection (c) surviving only to the extent relating to Intrexon Patents that are relevant to Retained Products that, to Intrexon’s knowledge, are
being developed or Commercialized at such time, if any), 4.10, 4.11, 7.1, 7.2, 7.4, 7.5, 10.4, and 10.5; Articles 9 (excluding 9.5), 11, and 12; and any relevant definitions in Article 1. Further, Article 7 and Sections 4.5(a), 4.5(c), 5.2 through
5.9, and 9.5 will survive termination of this Agreement only to the extent there are any applicable Retained Products. 

  
 46 

 ARTICLE 11 

DISPUTE RESOLUTION 

11.1    Disputes. It is the objective of the Parties to establish procedures to facilitate the resolution of
disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation to or in
connection with this Agreement (other than disputes arising from a Committee), including, without limitation, any alleged failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement,
then upon the request of either Party by written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person meeting
between the Executive Officers of each Party. If the matter is not resolved within thirty (30) days following the written request for discussions, either Party may then invoke the provisions of Section 11.2. For the avoidance of doubt, any
disputes, controversies or differences arising from a Committee pursuant to Article 2 shall be resolved solely in accordance with Section 2.4. 

11.2    Arbitration. Any dispute, controversy, difference or claim which may arise between the Parties and
not from a Committee, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance, application or
termination of this Agreement) that is not resolved pursuant to Section 11.1 shall, subject to Section 11.10, be settled by binding “baseball arbitration” as follows. Either Party, following the end of the thirty (30) day
period referenced in Section 11.1, may refer such issue to arbitration by submitting a written notice of such request to the other Party. Promptly following receipt of such notice, the Parties shall meet and discuss in good faith and seek to
agree on an arbitrator to resolve the issue, which arbitrator shall be neutral and independent of both Parties and all of their respective Affiliates, shall have significant experience and expertise in licensing and partnering agreements in the
pharmaceutical and biotechnology industries, and shall have some experience in mediating or arbitrating issues relating to such agreements. If the Parties cannot agree on a single arbitrator within fifteen (15) days of request by a Party for
arbitration, then each Party shall select an arbitrator meeting the foregoing criteria and the two (2) arbitrators so selected shall select within ten (10) days of their appointment a third arbitrator meeting the foregoing criteria. Within
fifteen (15) days after an arbitrator(s) is selected (in the case of the three-person panel, when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party a detailed written proposal setting forth
its proposed terms for the resolution for the matter at issue (the “Proposed Terms” of the Party) and a memorandum (the “Support Memorandum”) in support thereof. The Parties will also provide the arbitrator(s) a
copy of this Agreement, as it may be amended at such time. Within fifteen (15) days after receipt of the other Party’s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to the other Party) a
response to the other Party’s Support Memorandum. Neither Party may have any other communications (either written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as expressly permitted in this
Section 11.2; provided that, the arbitrator(s) may convene a hearing if the arbitrator(s) so chooses to ask questions of the Parties and hear oral argument and discussion regarding each Party’s Proposed Terms. Within sixty (60) days
after the arbitrator’s appointment, the arbitrator(s) will select one of the two Proposed 

  
 47 

 
Terms (without modification) provided by the Parties that he or she believes is most consistent with the intention underlying and agreed principles set forth in this Agreement. The decision of
the arbitrator(s) shall be final, binding, and unappealable. For clarity, the arbitrator(s) must select as the only method to resolve the matter at issue one of the two sets of Proposed Terms, and may not combine elements of both Proposed Terms or
award any other relief or take any other action. 
 11.3    Governing Law. This Agreement shall be
governed by and construed under the substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another
jurisdiction. 
 11.4    Award. Any award to be paid by one Party to the other Party as determined by the
arbitrator(s) as set forth above under Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by
law, be charged against the losing Party. Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 11, and agrees that, subject to the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16, judgment may be entered upon the final award in any United States District Court located in New York and that other courts may award full faith and credit to such judgment in order to enforce such award. The
award shall include interest from the date of any damages incurred for breach of the Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator(s). With respect to money damages, nothing contained herein shall be
construed to permit the arbitrator(s) or any court or any other forum to award consequential, incidental, special, punitive or exemplary damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for consequential,
incidental, special, punitive or exemplary damages. The only damages recoverable under this Agreement are direct compensatory damages. 

11.5    Costs. Each Party shall bear its own legal fees. The arbitrator(s) shall assess his or her costs,
fees and expenses against the Party losing the arbitration. 
 11.6    Injunctive Relief. Nothing in this
Article 11 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief,
concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. Specifically, the Parties agree that a material breach by either
Party of its obligations in Section 3.4 or Article 7 of this Agreement may cause irreparable harm to the other Party, for which damages may not be an adequate remedy. Therefore, in addition to its rights and remedies otherwise available at law,
including, without limitation, the recovery of damages for breach of this Agreement, upon an adequate showing of material breach of such Section 3.4 or Article 7, and without further proof of irreparable harm other than this acknowledgement,
such non-breaching Party shall be entitled to seek (a) immediate equitable relief, specifically including, but not limited to, both interim and permanent restraining orders and injunctions, without bond,
and (b) such other and further equitable relief as the court may deem proper under the circumstances. For the avoidance of doubt, nothing in this Section 11.6 shall otherwise limit a breaching Party’s opportunity to cure a material
breach as permitted in accordance with Section 10.2. 

  
 48 

 11.7    Confidentiality. The arbitration proceeding shall
be confidential and the arbitrator(s) shall issue appropriate protective orders to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator(s) to make) any public announcement
with respect to the proceedings or decision of the arbitrator(s) without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the
arbitrator(s), except as required in connection with the enforcement of such award or as otherwise required by applicable law. 

11.8    Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable
after termination of this Agreement for any reason. 
 11.9    Jurisdiction. For the purposes of this
Article 11, the Parties acknowledge their diversity and agree to accept the jurisdiction of any United States District Court located in New York for the purposes of enforcing or appealing any awards entered pursuant to this Article 11 and for
enforcing the agreements reflected in this Article 11 and agree not to commence any action, suit or proceeding related thereto except in such courts. 

11.10    Patent Disputes. Notwithstanding any other provisions of this Article 11, and subject to the
provisions of Section 6.2, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Intrexon Patents shall be submitted to a court of competent jurisdiction in the country in which such Patent was
filed or granted. 
 ARTICLE 12 

GENERAL PROVISIONS 

12.1    Use of Name. No right, express or implied, is granted by this Agreement to either Party to use in
any manner the name of the other or any other trade name or trademark of the other in connection with the performance of this Agreement, except that (a) either Party may use the name of the other Party as required by law or regulation and in
press releases accompanying quarterly and annual earnings reports approved by the Audit Committee of the issuer’s Board of Directors, and (b) Oragenics may use the Intrexon Trademarks in accord with the licenses and restrictions set forth
herein. 
 12.2    LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL,
CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO
LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES AVAILABLE FOR BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7. 

12.3    Independent Parties. Neither Party is the employee or legal representative of the other Party for
any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This Agreement shall not constitute, create, or in any way be interpreted as a joint venture, partnership, or business
organization of any kind. 

  
 49 

 12.4    Notice. All notices, including notices of address
change, required or permitted to be given under this Agreement shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms receipt of
such transmission with the other party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage prepaid,
return receipt requested. All such communications shall be sent to the address or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing): 

 

			
	If to Intrexon and/or Actobiotics:	 	 Intrexon Corporation
 20374 Seneca Meadows
Parkway
 Germantown, MD 20876
 Attention: Senior Vice
President, Health Sector
 Fax: (301) 556-9901

		
	with a copy to:	 	 Intrexon Corporation
 20374 Seneca Meadows
Parkway
 Germantown, MD 20876
 Attention: Legal Department

Fax: (301) 556-9902

		
	If to Oragenics:	 	 Oragenics, Inc.
 4902 Eisenhower
Boulevard,
 Suite 125,
 Tampa, FL 33634

Attention: Chief Executive Officer
 Fax: (813) 286-7904

		
	with a copy to:	 	 Shumaker, Loop & Kendrick, LLP
 101
E. Kennedy Blvd., Suite 2800
 Tampa, FL 33602
 Attention: Mark
Catchur, Esq.
 Fax: (813) 229-1660

 12.5    Severability. In the event any provision of this Agreement is held
to be invalid or unenforceable, the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 

12.6    Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not
constitute a waiver of any other or subsequent breach. 
 12.7    Entire Agreement; Amendment. This
Agreement, including any exhibits attached hereto, constitute the entire, final, complete and exclusive agreement between the 

  
 50 

 
Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement (including any prior confidentiality agreement between the
Parties). All information of Intrexon or Oragenics to be kept confidential by the other Party under any prior confidentiality agreement, as of the Effective Date, shall be maintained as Confidential Information by such other Party under the
obligations set forth in Article 7 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party. 

12.8    Non-assignability; Binding on Successors. Any attempted
assignment of the rights or delegation of the obligations under this Agreement shall be void without the prior written consent of the non-assigning or non-delegating
Party; provided, however, that either Party may assign its rights or delegate its obligations under this Agreement without such consent (a) to an Affiliate of such Party or (b) to its successor in interest in connection with any merger,
acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets, provided that such assignee agrees in writing to assume and be bound by the assignor’s obligations under this
Agreement. This Agreement shall be binding upon, and inure to the benefit of, the successors, executors, heirs, representatives, administrators and permitted assigns of the Parties. Notwithstanding the foregoing, in the event that either Party
assigns this Agreement to its successor in interest by way of merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets (whether this Agreement is actually assigned or is
assumed by such successor in interest or its affiliate by operation of law (e.g., in the context of a reverse triangular merger)), the intellectual property rights of such successor in interest or any of its Affiliates other than those licensed in
this Agreement shall be automatically excluded from the rights licensed to the other Party under this Agreement. 

12.9    Force Majeure. Neither Party shall be liable to the other for its failure to perform any of its
obligations under this Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including without limitation
earthquakes, governmental regulation, fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 

12.10    No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any
intellectual property, whether by implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement. 

12.11    Non-Solicitation. During the Term and for a period of one
(1) year following the end of the Term, neither Oragenics nor Intrexon may directly or indirectly solicit in order to offer to employ, engage in any discussion regarding employment with, or hire any employee of the other Party or an individual
who was employed by the other party within one (1) year prior to such solicitation, discussion, or hire, without the prior approval of such other Party. General employment solicitations or advertisements shall not be considered direct or
indirect solicitations, and are not prohibited under this Agreement. 

  
 51 

 12.12    Legal Compliance. The Parties shall review in
good faith and cooperate in taking such actions to ensure compliance of this Agreement with all applicable laws. 

12.13    Further Assurances. Intrexon shall cause Actobiotics to take such actions and do such things as may
be reasonably necessary to carry out the provisions of this Agreement applicable to Actobiotics and Intrexon shall refrain from taking any action that would reasonably be expected to cause Actobiotics to be unable to take such actions and do such
things as may be reasonably necessary to carry out the provisions of this Agreement applicable to Actobiotics. 

12.14    Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile,
PDF, or other means of electronic communication), each of which taken together will constitute one and the same instrument, and any of the Parties hereto may execute this Agreement by signing any such counterpart. 

[Remainder of page intentionally left blank.] 

  
 52 

 IN WITNESS WHEREOF, the Parties hereto
have duly executed this Exclusive Channel Collaboration Agreement. 
  

									
	INTREXON CORPORATION	 		 	ORAGENICS, INC.
					
	By:	 	 /s/ Gregory Frost
	 		 	BY:	 	 /s/ Michael Sullivan

	Name:	 	Gregory Frost, PhD	 		 	Name:	 	Michael Sullivan
	Title:	 	Senior Vice President, Health Sector	 		 	Title:	 	Chief Financial Officer
				
	INTREXON ACTOBIOTICS NV	 		 		 	
					
	By:	 	 /s/ Pieter Rottiers
	 		 		 	
	Name:	 	Pieter Rottiers	 		 		 	
	Title:	 	Chief Executive Officer	 		 		 	

 [SIGNATURE PAGE FOR EXCLUSIVE CHANNEL COLLABORATION AGREEMENT] 

 AMENDMENT TO EXCLUSIVE
CHANNEL COLLABORATION AGREEMENT 
 This AMENDMENT
TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Amendment”) is effective as of May 10, 2017 (the “Amendment
Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876
(“Intrexon”), INTREXON ACTOBIOTICS NV, a naamloze vennootschap under Belgian law with registered offices at Technologiepark 4, 9052 Zwijnaarde (CBE no. 0882.251.820 (Ghent), Belgium
(“Actobiotics”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A. (“Oragenics”).
Intrexon and Actobiotics together on the one hand and Oragenics on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 

A.    WHEREAS Intrexon, Actobiotics, and Oragenics are parties to that certain Exclusive
Channel Collaboration Agreement, effective June 9, 2015 (the “Agreement”), pursuant to which Intrexon and Actobiotics collectively appointed Oragenics as their exclusive channel collaborator for developing and
commercializing certain products in an exclusive field as defined by the Agreement; 

B.    WHEREAS the Intrexon, Actobiotics, and Oragenics all now mutually desire to amend the
Agreement; 
 D.    NOW, THEREFOR, the Intrexon, Actobiotics, and Oragenics
agree to amend the terms of the Agreement as provided below, effective as of the Amendment Effective Date. 
  

	1.	 GENERALLY 

1.1    Capitalized terms present within this Amendment that are not proper names or titles, that are not
conventionally capitalized, or that are not otherwise defined within this Amendment shall have the meaning set forth in the Agreement. 

1.2    Intrexon and Oragenics, in conjunction with and contemporaneously with this Amendment, have entered into an
Amendment to Stock Issuance Agreement of even date herewith (the “Stock Amendment”), which Stock Amendment amends the stock Issuance Agreement by and between Intrexon and Oragenics, effective June 9, 2015 (the
“Stock Agreement”). 
  

	2.	 AMENDMENTS TO THE AGREEMENT

 2.1    Definitions. Section 1.58 of the Agreement is hereby replaced in its
entirety with the following new Section 1.58: 
 “Phase II Milestone Event” means the earlier of (a) dosing of
the last patient by or on behalf of Oragenics, or an Affiliate or permitted sublicensee of Oragenics, in a phase II clinical trial (as such is defined by relevant FDA guidelines, irrespective of 

 
whether such occurs in the United States of America under the jurisdiction of the FDA or elsewhere under the jurisdiction of a foreign regulatory agency) for a given Oragenics Product, and
(b) the twenty four (24) month anniversary of the dosing of the first patient in the phase II clinical trial. For purposes of this Section 1.58, the “dosing of the last patient” shall mean the last patient planned for under
the JSC approved protocol (as such protocol may be amended and/or trial terminated during its implementation) for such phase II clinical trial having received his or her first dose. 

2.2    Milestones. Section 5.2(a)(i) of the Agreement is hereby replaced in its entirety with the
following new Section 5.2(a)(i): 
 Oragenics shall pay Intrexon a milestone payment of three million United States dollars
($3,000,000) within thirty (30) days of each achievement of the Phase II Milestone Event for each different Oragenics Product, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or
in shares of Oragenics’ common stock. A second or a subsequent occurrence of the Phase II Milestone Event shall only give rise to an obligation upon Oragenics to make the payment to Intrexon under this Section 5.2(a)(i) if such respective
second or subsequent occurrence of the Phase II Milestone Event occurs after the FDA has granted an approval to an FDA New Product Application for at least one Oragenics Product under the Program. 

 

	3.	 MISCELLANEOUS 

3.1    Full Force and Effect. This Amendment amends the terms of the Agreement and is deemed incorporated
into the Agreement. The provisions of the Agreement as amended remain in full force and effect. 

3.2    Entire Agreement. This Amendment, together with the Agreement, the Stock Agreement, and the Stock
Amendment, constitutes the entire agreement, both written and oral, between the Parties with respect to the subject matter hereof, and any and all prior agreements with respect to the subject matter hereof, either written or oral, expressed or
implied, are superseded hereby, merged and canceled, and are null and void and of no effect. 

3.3    Counterparts. This Amendment may be executed in one or more counterparts, each of which will be an
original and all of which together will constitute one instrument. 

  
 55 

 IN WITNESS WHEREOF,
Intrexon, Actobiotics, and Oragenics have executed this Amendment by their respective duly authorized representatives as of the Amendment Effective Date. 
  

									
	INTREXON CORPORATION	 		 	ORAGENICS, INC.
					
	By:	 	 /s/ Donald P. Lehr
	 		 	By:	 	 /s/ Alan Joslyn

	Name:	 	Donald P. Lehr	 		 	Name:	 	Alan Joslyn
	Title:	 	Chief Legal Officer	 		 	Title:	 	President and CEO

  

			
	INTREXON ACTOBIOTICS NV
		
	By:	 	/s/ Christian Ulrich
	Name:	 	Christian Ulrich
	Title:	 	Director

 Signature Page to Amendment to Exclusive Channel Collaboration Agreement 

 SECOND AMENDMENT TO EXCLUSIVE
CHANNEL COLLABORATION AGREEMENT 
 This SECOND AMENDMENT
TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Amendment”) is effective as of November 8, 2017 (the “Amendment Effective
Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”),
INTREXON ACTOBIOTICS NV, a naamloze vennootschap under Belgian law with registered offices at Technologiepark 4, 9052 Zwijnaarde (CBE no. 0882.251.820 (Ghent), Belgium (“Actobiotics”), and
ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A. (“Oragenics”). Intrexon and Actobiotics together on
the one hand and Oragenics on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 

A.    WHEREAS Intrexon, Actobiotics, and Oragenics are parties to that certain Exclusive
Channel Collaboration Agreement, effective June 9, 2015, as amended by that certain Amendment to Exclusive Channel Collaboration Agreement, effective May 10, 2017 (the “Agreement”), pursuant to which Intrexon and
Actobiotics collectively appointed Oragenics as their exclusive channel collaborator for developing and commercializing certain products in an exclusive field as defined by the Agreement; 

B.    WHEREAS Intrexon, Actobiotics, and Oragenics all now mutually desire to amend the
Agreement; 
 D.    NOW, THEREFORE, Intrexon, Actobiotics, and Oragenics
agree to amend the terms of the Agreement as provided below, effective as of the Amendment Effective Date. 
  

	4.	 GENERALLY 

a.    Capitalized terms present within this Amendment that are not proper names or titles, that are not conventionally
capitalized, or that are not otherwise defined within this Amendment shall have the meaning set forth in the Agreement. 

b.    Intrexon and Oragenics, in conjunction with and contemporaneously with this Amendment, have entered into an
Amendment to Stock Issuance Agreement of even date herewith (the “Stock Amendment”), which Stock Amendment amends the stock Issuance Agreement by and between Intrexon and Oragenics, effective June 9, 2015, as amended by that
certain Amendment to Stock Issuance Agreement, effective May 10, 2017 (the “Stock Agreement”). 

	5.	 AMENDMENTS TO THE AGREEMENT

 c.    Definitions. 

i.    Section 1.6 of the Agreement “Approval Milestone Event”, Section 1.58 of the Agreement
“Phase II Milestone Event”, Section 1.59 of the Agreement “Phase IIb/III Milestone Event”, and Section 1.60 of the Agreement “Prior Field” are hereby deleted in their entirety and each
replaced with “Reserved”. 
 ii.    Section 1.14 of the Agreement is hereby replaced in its entirety with the
following new Section 1.14: 
 “Commercialization Milestone Event” means any one of the Regulatory Approval Milestone
Event, the New Indication Milestone Event, and the New Product Milestone Event. 
 iii.    Section 1.27 of the Agreement
is hereby replaced in its entirety with the following new Section 1.27: 
 “Field” means, irrespective of whether such
requires regulatory approval, the treatment of oral mucositis in humans through the administration of an effector via genetically modified bacteria. Notwithstanding the foregoing, the Field shall exclude the delivery of anti-cancer effectors
for the purpose of treatment or prophylaxis of cancer. 
 iv.    Section 1.50 of the Agreement is hereby replaced in its
entirety with the following new Section 1.50: 
 “New Indication Milestone Event” means for a given Oragenics Product,
the approval of a Supplemental FDA Application with the FDA (or an equivalent filing with another equivalent regulatory agency) which Supplemental FDA Application sought approval of an indication for use of an Oragenics Product other than the
current regulatory-approved indication for the respective Oragenics Product. Notwithstanding the foregoing and in order to incentivize Oragenics to pursue new indications for the product AG013 in parallel with the existing indication (as such
existing indication is described in Investigational Drug Application no. 13995) for product AG013, the New Indication Milestone Event will be deemed not to have occurred if the filed regulatory package under the prior sentence relies upon one
or more human clinical trials for the specific new indication, which clinical trial(s) were conducted simultaneously and in parallel with human clinical trials underpinning the first-approved indication for AG013. For the avoidance of doubt and
clarification purposes, any occurrence of the New Indication Milestone Event shall not also be deemed the occurrence of the New Product Milestone Event or vice versa. 

  
 3 

 v.    Section 1.51 of the Agreement is hereby replaced in its entirety
with the following new Section 1.51: 
 “New Product Milestone Event” means for a given Oragenics Product, the approval of
a FDA New Product Application for such Oragenics Product that is deemed (according to relevant FDA guidelines) to be a different drug product than the first Oragenics Product that was clinically pursued under the Program. For purposes of the New
Product Milestone Event, the subject Oragenics Product shall be deemed to be a “different” Oragenics Product from the first Oragenics Product (and thus constitute an occurrence of the New Product Milestone Event) if regulatory approval of
the subject Oragenics Product had to be obtained from the FDA under a different FDA New Product Application than the first Oragenics Product. For the avoidance of doubt and clarification purposes, any occurrence of the New Product Milestone Event
shall not also be deemed the occurrence of the New Indication Milestone Event or vice versa. 
 vi.    Section 1.68 of
the Agreement is hereby replaced in its entirety with the following new Section 1.68: 
 “Regulatory Approval Milestone
Event” means for a given Oragenics Product, the approval of a FDA New Product Application for such Oragenics Product by the FDA or equivalent regulatory action in a foreign jurisdiction. 

vii.    Section 1.74(a) of the Agreement “Sublicensing Revenue Rate” is hereby amended by deleting
“Sublicensing Revenue Rate shall be fifty percent (50%)” and replacing it with “Sublicensing Revenue Rate shall be twenty five percent (25%)”. 

d. Milestones. Section 5.2(a) of the Agreement is hereby replaced in its entirety with the following new Section 5.2(a) and all
references in the Agreement to Sections 5.2(a)(i) through 5.2(a)(vi) shall refer to Sections 5.2(a)(i) through 5.2(a)(iii): 

viii.    Oragenics Commercialization Milestones. Upon the first instance of attainment of certain Commercialization
Milestone Events by an Oragenics Product (whether such attainment is achieved by Oragenics or by a permitted sublicensee), Oragenics has agreed to pay Intrexon milestone payments as set forth in this Section 5.2. The milestone payments are each
payable, at Oragenics’ election but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’ common stock (using Fair Market Value, as defined in the Equity Agreement, to calculate the number of shares to be
issued to Intrexon in lieu of cash). The specific milestone 

  
 4 

 
payments due to Intrexon upon achievement of each of the Commercialization Milestone Events are set forth in Sections 5.2(a)(i) through 5.3(a)(iii) below. 

(i)     Oragenics shall pay Intrexon a milestone payment of twenty seven million five hundred thousand
United States dollars ($27,500,000) within six (6) months of the first instance of the achievement of the Regulatory Approval Milestone Event, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d),
either in cash or in shares of Oragenics’ common stock. 
 (ii)    Oragenics shall pay Intrexon a one-time milestone payment of five million United States dollars ($5,000,000) within six (6) months of the first instance of the achievement of the New Indication Milestone Event, said payment being made, at
Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’ common stock. 

(iii)    Oragenics shall pay Intrexon a one-time milestone payment
of five million United States dollars ($5,000,000) within six (6) months of the first instance of the achievement of the New Product Milestone Event, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through
5.2(d), either in cash or in shares of Oragenics’ common stock. 
 Notwithstanding anything in this Agreement to the
contrary, but subject to its obligation under Section 4.5(a), Oragenics shall have sole and exclusive control over clinical trials (including patient dosing) and regulatory filings (including the jurisdictions in which such filings are made)
for the purpose of the Commercialization Milestones in Section 5.2(a)(i)-(iii) as applicable. 
  

	6.	 MISCELLANEOUS 

6.1    Full Force and Effect. This Amendment amends the terms of the Agreement and is deemed incorporated
into the Agreement. The provisions of the Agreement as amended remain in full force and effect. 

6.2    Entire Agreement. This Amendment, together with the Agreement, the Stock Agreement, and the Stock
Amendment, constitutes the entire agreement, both written and oral, between the Parties with respect to the subject matter hereof, and any and all prior agreements with respect to the subject matter hereof, either written or oral, expressed or
implied, are superseded hereby, merged and canceled, and are null and void and of no effect. 

6.3    Counterparts. This Amendment may be executed in one or more counterparts, each of which will be an
original and all of which together will constitute one instrument. 

  
 5 

 IN WITNESS WHEREOF,
Intrexon, Actobiotics, and Oragenics have executed this Amendment by their respective duly authorized representatives as of the Amendment Effective Date. 
  

									
	INTREXON CORPORATION	 		 	ORAGENICS, INC.
					
	By:	 	 /s/ Donald P. Lehr
	 		 	By:	 	 /s/ Alan Joslyn

	Name:	 	Donald P. Lehr	 		 	Name:	 	Alan Joslyn
	Title:	 	Chief Legal Officer	 		 	Title:	 	Chief Executive Officer
				
	INTREXON ACTOBIOTICS NV	 		 		 	
					
	By:	 	 /s/ Ricky Sterling
	 		 		 	
	Name:	 	Ricky Sterling	 		 		 	
	Title:	 	Director	 		 		 	

 Signature Page to Amendment to Exclusive Channel Collaboration Agreement

			
	December 29, 2017	  	INTREXON

 VIA FACSIMILE: (813) 286-7904 

Oragenics, Inc. 
 4902 Eisenhower Boulevard, Suite 125 

Tampa, FL 33634 
 Attention: Chief Executive Officer 

VIA FACSIMILE: (813) 229-1660 

Shumaker, Loop & Kendrick, LLP 
 101 E. Kennedy
Boulevard, Suite 2800 
 Tampa, FL 33602 
 Attention: Mark
Catchur, Esq. 
  

	Re:	 Notice of Assignment - Exclusive Channel Collaboration Agreement effective June 9, 2015

 Dear Sirs: 
 We are pleased to advise
that Intrexon Corporation has reorganized certain of its operating divisions, including the formation of a new wholly owned subsidiary of Intrexon Corporation, ActoBio Therapeutics, Inc. (“ActoBio”). ActoBio will include all of
Intrexon’s worldwide operations relating to its ActobioticTM L. lactis human therapeutic platform, including products and programs being pursued in collaboration with Oragenics, Inc. (“Oragenics”). This internal reorganization
will not negatively impact Oragenics or this collaboration. 
 This letter is Notice that effective January 1, 2018 and as permitted by
Section 12.8 of the Exclusive Channel Collaboration Agreement effective June 9, 2015 (the “Agreement”) Intrexon Corporation has assigned Intrexon Corporation’s interests in this Agreement to ActoBio. ActoBio Therapeutics,
Inc. agrees to be bound by the Agreement and assumes all rights, interest and obligations under the Agreement previously held by Intrexon Corporation. For your future use and reference, contact and correspondence addresses are provided on the
attached sheet. 
 Please do not hesitate to contact my office if you have any questions and we appreciate your attention to this matter. 

Best regards, 
 INTREXON CORPORATION 

/s/ Donald P.
Lehr                                         
        
 Donald P. Lehr 

Chief Legal Officer 
 Attachment 

20374 Seneca Meadows Parkway        Germantown, MD 20876        301-556-9900        Facsimile:
301-556-9902 

  
 2Exhibit 4.2

 

NEITHER THESE SECURITIES NOR THE SECURITIES
ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”) AND APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO (I) AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR (II) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.
THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

ETON
PHARMACEUTICALS, INC. 

 

WARRANT
TO PURCHASE COMMON STOCK

 

	Warrant No. E-100	Original Issue Date:  May 4, 2017

 

Eton Pharmaceuticals, Inc., a Delaware
corporation (the “Company”), hereby certifies that, for value received, Liquid Patent Advisors, LLC or
his permitted registered assigns (the “Holder”), is entitled to purchase from the Company up to a total
of 600,000 shares of common stock, $0.001 par value (the “Common Stock”), of the Company (each such share,
a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise
price per share equal to $0.01 (as adjusted from time to time as provided in Section 9 herein, the “Exercise
Price”), at any time and from time to time from on or after the date hereof (the “Trigger Date”)
and through and including 5:00 P.M., prevailing Pacific time, on May 4, 2022 (the “Expiration Date”),
and subject to the following terms and conditions:

 

This Warrant (this
“Warrant”) is issued pursuant to that certain Engagement Agreement for Strategic Consulting Services
dated May 4, 2017 between the Company and Holder (the “Consulting Agreement”).

 

1.           Definitions.
In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings
given to such terms in the Consulting Agreement.

 

2.           Registration
of Warrants. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any
registered assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

     

     

    

 

3.           Registration
of Transfers. The Company shall register the transfer of all or any portion of this Warrant in the Warrant Register, upon
(i) surrender of this Warrant, with the Form of Assignment attached as Schedule 2 hereto duly completed and signed, to
the Company’s transfer agent or to the Company at its address specified herein (ii) delivery, at the request of the Company,
of an opinion of counsel reasonably satisfactory to the Company to the effect that the transfer of such portion of this Warrant
may be made pursuant to an available exemption from the registration requirements of the Securities Act of 1933 (“Securities
Act”) and all applicable state securities or blue sky laws and (iii) delivery by the transferee of a written statement
to the Company certifying that the transferee is an “accredited investor” as defined in Rule 501(a) under the Securities
Act and making the representations and certifications as the Company may reasonably request to procure an exemption from Section
5 of the Securities Act. Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form
of this Warrant (any such new warrant, a “New Warrant”) evidencing the portion of this Warrant so transferred
shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any,
shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance
by such transferee of all of the rights and obligations of a Holder of a Warrant.

 

4.           Exercise
and Duration of Warrants.

 

(a)          All
or any part of this Warrant shall be exercisable by the registered Holder at any time and from time to time on or after the Trigger
Date and through and including 5:00 P.M. prevailing Pacific time on the Expiration Date. At 5:00 P.M., prevailing Pacific time,
on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value and this
Warrant shall be terminated and no longer outstanding.

 

(b)          The
Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1
hereto (the “Exercise Notice”), appropriately completed and duly signed, (ii) payment of the Exercise
Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a “cashless
exercise” if so indicated in the Exercise Notice and if a “cashless exercise” may occur at such time pursuant
to Section 10 below), and the date such items are delivered to the Company (as determined in accordance with the notice
provisions hereof) is an “Exercise Date.” The Holder shall not be required to deliver the original Warrant
in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation
of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.

 

    	 	Page 2 of 14	 

     

    

 

5.           Delivery
of Warrant Shares. Upon exercise of this Warrant, the Company shall promptly issue or cause to be issued and cause to be delivered
to or upon the written order of the Holder and in such name or names as the Holder may designate a certificate for the Warrant
Shares issuable upon such exercise, with an appropriate restrictive legends. The Holder, or any Person permissibly so designated
by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the
Exercise Date.

 

6.           Charges,
Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect
of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however,
that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration
of any certificates for Warrant Shares or Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder
shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving
Warrant Shares upon exercise hereof.

 

7.           Replacement
of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon
receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case,
a customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a New Warrant under
such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party
costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder
shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the New
Warrant.

 

8.           Reservation
of Warrant Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate of its
authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon
exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise
of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking
into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable
and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be
duly and validly authorized, issued and fully paid and nonassessable. The Company will take all such action as may be necessary
to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of any securities exchange or automated quotation system upon which the Common Shares may be listed.

 

    	 	Page 3 of 14	 

     

    

 

9.           Certain
Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment
from time to time as set forth in this Section 9.

 

(a)          Stock
Dividends and Splits; Holder Electoral Adjustment. If the Company, at any time while this Warrant is outstanding, (i) pays
a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares
of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares, or (iii) combines its outstanding
shares of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction,
the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator
of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to
clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective
immediately after the effective date of such subdivision or combination. The Exercise Price of this Warrant may be adjusted upward
at the sole discretion of the Holder for a period of twelve (12) months following the Original Issue Date of the Warrant.

 

(b)          Fundamental
Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the
Company with or into another Person, in which the Company is not the survivor, (ii) the Company effects any sale of all or substantially
all of its assets or a majority of its Common Stock is acquired by a third party, in each case, in one or a series of related transactions,
(iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which all or substantially
all of the holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or
(iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision
or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”),
then the Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities,
cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been,
immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full
of this Warrant without regard to any limitations on exercise contained herein (the “Alternate Consideration”).
The Company shall not effect any such Fundamental Transaction unless prior to or simultaneously with the consummation thereof,
any successor to the Company, surviving entity or the corporation purchasing or otherwise acquiring such assets or other appropriate
corporation or entity shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with
the foregoing provisions, the Holder may be entitled to purchase and/or receive (as the case may be), and the other obligations
under this Warrant. The provisions of this paragraph (b) shall similarly apply to subsequent transactions analogous to a Fundamental
Transaction.

 

    	 	Page 4 of 14	 

     

    

 

(c)          Number
of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to paragraph (a) of this Section, the
number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so
that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares
shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment.

 

(d)          Calculations.
All calculations under this Section 9 shall be made to the nearest cent or the nearest 1/100th of a share, as
applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for
the account of the Company, and the sale or issuance of any such shares shall be considered an issue or sale of Common Stock.

 

(e)          Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will,
at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant
and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number
or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions
giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the
Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

 

(f)          Notice
of Corporate Events. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of
cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants
to subscribe for or purchase any capital stock of the Company, (ii) authorizes or approves, enters into any agreement contemplating
or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or
winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material
non-public information, the Company shall deliver to the Holder a notice describing the material terms and conditions of such transaction
at least ten (10) Trading Days prior to the applicable record or effective date on which a Person would need to hold Common Stock
in order to participate in or vote with respect to such transaction, and the Company will take all steps reasonably necessary in
order to insure that the Holder is given the practical opportunity to exercise this Warrant prior to such time so as to participate
in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect
therein shall not affect the validity of the corporate action required to be described in such notice.

 

10.         Payment
of Exercise Price. The Holder shall pay the Exercise Price in immediately available funds; provided, however,
the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a “cashless exercise”,
in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows:

 

    	 	Page 5 of 14	 

     

    

 

X = Y [(A-B)/A]

 

where:

 

X = the number of Warrant Shares
to be issued to the Holder.

 

Y = the total number of Warrant
Shares with respect to which this Warrant is being exercised.

 

A = the average of the Closing
Sale Prices of the shares of Common Stock (as reported by Bloomberg Financial Markets) for the five Trading Days ending on the
date immediately preceding the Exercise Date.

 

B = the Exercise Price then in
effect for the applicable Warrant Shares at the time of such exercise.

 

For purposes of this Warrant, “Closing
Sale Price” means, for any security as of any date, the last trade price for such security on the principal securities
exchange or trading market for such security, as reported by Bloomberg Financial Markets, or, if such exchange or trading market
begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security
prior to 4:00:00 p.m., New York Time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade
price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg
Financial Markets, or, if no last trade price is reported for such security by Bloomberg Financial Markets, the average of the
bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets”
by Pink Sheets LLC. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing
bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company
and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Company
shall, within two business days submit via facsimile (a) the disputed determination of the Warrant Exercise Price to an independent,
reputable investment bank selected by the Company and approved by the Holder or (b) the disputed arithmetic calculation of the
Warrant Shares to the Company’s independent, outside accountant. The Company shall cause at its expense the investment bank
or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the
results no later than ten business days from the time it receives the disputed determinations or calculations. Such investment
bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable
error. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar
transaction during the applicable calculation period.

 

For purposes of Rule 144 promulgated under
the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction
shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced,
on the date this Warrant was originally issued pursuant to the Consulting Agreement (provided that the Commission continues to
take the position that such treatment is proper at the time of such exercise).

 

    	 	Page 6 of 14	 

     

    

 

11.         Limitation
on Exercises. The Company shall not effect the exercise of this Warrant, and the Holder shall not have the right to exercise
this Warrant, to the extent that after giving effect to such exercise, the Holder (together with such Holder’s affiliates)
would beneficially own in excess of 4.99% (“Maximum Percentage”) of the shares of Common Stock outstanding
immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common
Stock beneficially owned by such Holder and its affiliates shall include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock
which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Holder
and its affiliates and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company
beneficially owned by such Person and its affiliates (including, without limitation, any convertible notes or convertible preferred
stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set
forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended. To the extent that the limitation contained in this Section 11
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any affiliate) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the
submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any affiliate) and of which portion of this Warrant is exercisable,
in each case subject to such aggregate percentage limitation, and the Company shall have no obligation to verify or confirm the
accuracy of the determination. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock,
the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Form
10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange Commission, as the case may
be, (2) a more recent public announcement by the Company or (3) any other notice by the Company setting forth the number
of shares of Common Stock outstanding. For any reason at any time, upon the written or oral request of the Holder, the Company
shall within one (1) business day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise
of securities of the Company, including this Warrant, by the Holder and its affiliates since the date as of which such number
of outstanding shares of Common Stock was reported. By written notice to the Company, any Holder may decrease the Maximum Percentage
to any other percentage specified in such notice; provided that such decrease will apply only to the Holder sending such notice
and not to any other holder of Warrants. In addition, by written notice to the Company, any Holder may remove the limitations
on exercises provided in this Section 11 entirely; provided that (i) any such removal will not be effective until the 61st
day after such notice is delivered to the Company, and (ii) any such removal will apply only to the Holder sending such notice
and not to any other holder of Warrants. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 11 to correct this paragraph (or any portion hereof) which may
be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation.

 

    	 	Page 7 of 14	 

     

    

 

12.         No
Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of
any fractional shares which would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded up to the
next whole number.

 

13.         Notices.
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall
be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication
is delivered via email at the email address specified in the Consulting Agreement prior to 5:00 p.m. (prevailing Pacific time)
on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via email
at the email address specified in the Consulting Agreement t on a day that is not a Trading Day or later than 5:00 p.m.. (prevailing
Pacific time) on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight
courier service specifying next business day delivery, or (iv) upon actual receipt by the party to whom such notice is required
to be given, if by hand delivery. The address and facsimile number of a party for such notices or communications shall be as set
forth in the Consulting Agreement unless changed by such party by two Trading Days’ prior notice to the other party in accordance
with this Section 13.

 

14.         Warrant
Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty (30) days’ notice to the Holder, the
Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any
corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation
to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business
shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly
cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s
last address as shown on the Warrant Register.

 

15.         Registration
Rights. The Company agrees that the Holder and its assigns will have registration rights covering the resale of the Warrant
Shares, including “piggyback” registration rights on the registrations of the Company or demand registrations (voting
with the other registrable securities to effect any such demand), no less favorable than those granted to any other person by
the Company prior or subsequent to the date of this Warrant. At such time, and from time to time, as the Company enters into an
agreement subsequent to the date of this Warrant pursuant to which the Company grants any third party rights with respect to the
Company’s registration of Company securities under the Securities Act held by such party, the Company shall offer to enter
into a formal written registration rights agreement with the Holder and its assigns on substantially the same terms and such other
terms as are customary and usual for agreements of such nature. In addition to, and without restricting or limiting the scope
of this subparagraph (a), the Company further agrees that

 

    	 	Page 8 of 14	 

     

    

 

(a)          Right
to Piggyback. Whenever the Company proposes to register any of its securities under the Securities Act, the Company will give
prompt written notice to the Holder of its intention to effect such registration and will include in such registration all Warrant
Shares with respect to which the Company has received a written request from the Holder for inclusion therein within 15 days after
the receipt of the Company’s notice. The Company will pay, or cause to be paid, the registration expenses of the Holder in
all piggyback registrations.

 

(b)          Underwritten
Offering. If a piggyback registration is an underwritten primary or secondary registration on behalf of the Company and/or
other holders of the Common Stock, and the managing underwriters advise the Company in writing that in their opinion the number
of shares requested to be included in such registration (including the Warrant Shares and any other shares of Common Stock held
by holders with registration rights) exceeds the number which can be sold in such offering without materially and adversely affecting
the marketability of the offering, the Company will promptly furnish the Holder with a copy of the underwriter’s opinion
and may, by written notice to the Holder, include in such registration (i) first, the securities the Company proposes to sell,
(ii) second, the Common Stock requested to be included in such registration pro rata among all holders with registration rights
on the basis of the number of shares owned by each such holder, and (iii) third, exclude all the Common Stock requested to be included
in such registration statement of all holders with registration rights.

 

(c)          Underwriting
Agreement. In any registration in which the Warrant Shares is to be included, the Holder shall be a party to the underwriting
agreement entered into by the Company in connection therewith, and the representations and warranties by, and the other agreements
on the part of, the Company and for the benefit of the underwriters shall also be made to and for the benefit of the Holder.

 

(d)          Documents,
etc. The Company shall provide to the Holder any and all documents, statements, opinions and forms as the Holder reasonably
deems necessary for the Holder to participate in any piggyback registrations and to facilitate the disposition of the Warrant Shares
covered by such registration pursuant to the terms and conditions of this Agreement and the applicable securities laws.

 

(e)          Indemnification.
In the event of any piggyback registration of any Warrant Shares under the Securities Act, and in connection with any registration
statement or any other disclosure document pursuant to which securities of the Company are sold, the Company will, and hereby does,
jointly and severally, indemnify and hold harmless the Holder, its directors, officers, fiduciaries, and agents (each, a “Covered
Person”) against any losses, claims, damages or liabilities, joint or several, to which such Covered Person may be
or become subject under the Securities Act, any other securities or other laws of any jurisdiction, common law or otherwise, insofar
as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of or are based upon (1)
any untrue statement or alleged untrue statement of any material fact contained or incorporated by reference in any registration
statement under the Securities Act, any preliminary prospectus or final prospectus included therein, or any amendment or supplement
thereto, or any document incorporated by reference therein, or any other such disclosure document, or (2) any omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the statement therein not misleading,
and will reimburse such Covered Person for any legal or any other expenses incurred by in connection with investigating or defending
any such loss, claim, damage, liability, action or proceeding; provided, however, the Company shall not be liable to any Covered
Person in any such case to the extent that any such loss, claim, damage, liability, action or proceeding is determined, by a final,
non-appealable judgment by a court or arbitral tribunal of competent jurisdiction, to have arisen out of or is based upon an untrue
statement or alleged untrue statement or omission or alleged omission made in such registration statement, any such preliminary
prospectus, final prospectus, amendment or supplement, any document incorporated by reference or other such disclosure document
in reliance upon and in conformity with written information furnished to the Company through an instrument duly executed by such
Covered Person specifically stating this it is for use in the preparation thereof.

 

    	 	Page 9 of 14	 

     

    

 

(f)          All
fees and expenses incurred by the Company in connection with the performance of its obligation to register the Warrant Shares pursuant
to Section 15 shall be borne by the Company; provided that any fees and expenses of the holder or holders thereof or of
its or their counsel, and transfer taxes applicable to the sale of such Warrant Shares, shall be borne by such holder or holders.

 

16.         Miscellaneous.

 

(a)          The
Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends
or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed
to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder
of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends
or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled
to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing
any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the
Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 16(a),
the Company shall provide the Holder with copies of the same notices and other information given to the shareholders of the Company,
contemporaneously with the giving thereof to the shareholders.

 

(b)          Subject
to the restrictions on transfer set forth on the first page hereof, and compliance with applicable securities laws, this Warrant
may be assigned by the Holder. This Warrant may not be assigned by the Company except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and
assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company
and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in
writing signed by the Company and the Holder, or their successors and assigns.

 

    	 	Page 10 of 14	 

     

    

 

(c)          GOVERNING
LAW; VENUE; WAIVER OF JURY TRIAL. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA WITHOUT REGARD TO
THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND
FEDERAL COURTS SITTING IN THE CITY OF LOS ANGELES, CALIFORNIA, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH
OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION
DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT
PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY
WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY
THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT
FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND
NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED
BY LAW. THE COMPANY HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

 

(d)          The
headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.

 

(e)          In
case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the parties will
attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

(f)          Except
as otherwise set forth herein, prior to exercise of this Warrant, the Holder hereof shall not, by reason of by being a Holder,
be entitled to any rights of a stockholder with respect to the Warrant Shares.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,

SIGNATURE PAGE FOLLOWS]

 

    	 	Page 11 of 14	 

     

    

 

IN WITNESS WHEREOF, the Company has caused
this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	 	Eton Pharmaceuticals, Inc.,
	 	a Delaware corporation
	 	 
	 	By:	/s/ Mark L. Baum
	 	Mark L. Baum, Executive Director

 

    	 	Page 12 of 14	 

     

    

 

SCHEDULE 1

FORM OF EXERCISE NOTICE

 

(To be executed by the Holder to exercise the right to purchase
shares

of Common Stock under the foregoing Warrant)

 

Ladies and Gentlemen:

 

(1)         The
undersigned is the Holder of Warrant No. ____________ (the “Warrant”) issued by Eton Pharmaceuticals,
Inc., a Delaware corporation (the “Company”). Capitalized terms used herein and not otherwise defined
herein have the respective meanings set forth in the Warrant.

 

(2)         The
undersigned hereby exercises its right to purchase ____________ Warrant Shares pursuant to the Warrant.

 

(3)         The
Holder intends that payment of the Exercise Price shall be made as (check one):

 

Cash Exercise

 

“Cashless Exercise”
under Section 10

 

(4)         If
the Holder has elected a Cash Exercise, the Holder shall pay the sum of $_________ in immediately available funds to the Company
in accordance with the terms of the Warrant.

 

(5)         Pursuant
to this Exercise Notice, the Company shall deliver to the Holder ____________ Warrant Shares in accordance with the terms of the
Warrant.

 

Dated: __________________, _______

	Name
of Holder:	 	 

	By:	 	 
	Name:	 	 
	Title:	 	 

(Signature must conform in all respects to name of Holder as
specified on the face of the Warrant)

 

    	 	Page 13 of 14	 

     

    

 

SCHEDULE 2

FORM OF ASSIGNMENT

 

[To be completed and signed only upon transfer
of Warrant]

 

FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto __________ (the “Transferee” the right represented by the within Warrant
to purchase __________ shares of Common Stock of Eton Pharmaceuticals, Inc. (the “Company”) to which
the within Warrant relates and appoints __________ attorney to transfer said right on the books of the Company with full power
of substitution in the premises. In connection therewith, the undersigned represents, warrants, covenants and agrees to and with
the Company that:

 

(a)          the
offer and sale of the Warrant contemplated hereby is being made in compliance with Section 4(a)(1) of the United States Securities
Act of 1933, as amended (the “Securities Act”) or another valid exemption from the registration requirements
of Section 5 of the Securities Act and in compliance with all applicable securities laws of the states of the United States;

 

(b)          the
undersigned has not offered to sell the Warrant by any form of general solicitation or general advertising, including, but not
limited to, any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or
broadcast over television or radio, and any seminar or meeting whose attendees have been invited by any general solicitation or
general advertising;

 

(c)          the
undersigned has read the Transferee’s investment letter included herewith, and to its actual knowledge, the statements made
therein are hue and correct; and

 

(d)          the
undersigned understands that the Company may condition the transfer of the Warrant contemplated hereby upon the delivery to the
Company by the undersigned or the Transferee, as the case may be, of a written opinion of counsel (which opinion shall be in form,
substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made
without registration under the Securities Act and under applicable securities laws of the states of the United States.

 

	Dated: ______, __	 	 
	 	 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
	 	 	 
	 	 	 
	 	 	Address of Transferee
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	In the presence of:	 	 	 

 

    	 	Page 14 of 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]